{"gene":"CBX7","run_date":"2026-06-09T22:57:17","timeline":{"discoveries":[{"year":2003,"finding":"CBX7 interacts with Ring1 and localizes to nuclear Polycomb bodies, functioning as a PRC1 component to repress the Ink4a/Arf locus and extend cellular lifespan; shRNA ablation of CBX7 induced growth arrest via induction of Ink4a/Arf.","method":"Co-immunoprecipitation (Ring1 interaction), immunofluorescence (nuclear Polycomb body localization), shRNA knockdown with p16/Arf induction readout, cDNA screen for senescence bypass","journal":"Nature cell biology","confidence":"High","confidence_rationale":"Tier 2 / Strong — reciprocal functional validation (overexpression + shRNA KD), localization confirmed, replicated mechanistic readout across multiple cell types","pmids":["14647293"],"is_preprint":false},{"year":2010,"finding":"CBX7 within PRC1 binds directly to the noncoding RNA ANRIL via its chromodomain; in concert with H3K27me3 recognition, RNA binding is required for CBX7-mediated repression of the INK4b/ARF/INK4a locus. Structure-guided analysis revealed the molecular interplay between noncoding RNA and H3K27me3 as mediated by the conserved chromodomain.","method":"RNA immunoprecipitation, NMR structural analysis of chromodomain–RNA interaction, chromodomain mutants disrupting RNA or H3K27me binding, ChIP at INK4a/ARF locus, senescence assays","journal":"Molecular cell","confidence":"High","confidence_rationale":"Tier 1 / Strong — structural analysis combined with mutagenesis and functional validation, multiple orthogonal methods in one study","pmids":["20541999"],"is_preprint":false},{"year":2005,"finding":"CBX7 represses p16INK4a and p14ARF expression in normal and tumor-derived prostate cells; shRNA knockdown upregulates both p16 and p14ARF and impairs cell growth in a manner dependent on the p16/Rb and p14ARF/p53 pathway status.","method":"shRNA knockdown, Western blot for p16/p14ARF, growth assays in LNCaP and PC-3 cells","journal":"Oncogene","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — clean KD with defined pathway-level readout, single lab, two cell line models","pmids":["15897876"],"is_preprint":false},{"year":2007,"finding":"CBX7 represses the Ink4a/Arf locus and acts epistatically to the Arf-p53 pathway during lymphomagenesis in vivo; transgenic targeting of Cbx7 to the lymphoid compartment initiated T cell lymphomagenesis and cooperated with c-Myc to produce B cell lymphomas.","method":"Transgenic mouse model (lymphoid-targeted Cbx7 expression), genetic epistasis with Arf-p53 pathway, tumor characterization","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"High","confidence_rationale":"Tier 2 / Strong — in vivo epistasis in transgenic mouse model with defined pathway placement, replicated across lymphoma types","pmids":["17374722"],"is_preprint":false},{"year":2009,"finding":"CBX7 (PRC1 component) physically associates with DNA methyltransferase (DNMT) enzymes; CBX7 can initiate stable repression and promoter DNA hypermethylation of cancer-silenced genes in embryonal carcinoma cells, and DNMTs are assembled at CBX7 target gene promoters.","method":"Co-immunoprecipitation (CBX7–DNMT interaction), ChIP (DNMT assembly at CBX7 target promoters), CBX7 knockdown/sustained expression in EC cells, epigenomic analysis","journal":"Cancer research","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — Co-IP plus ChIP plus functional gain/loss experiments, single lab","pmids":["19602592"],"is_preprint":false},{"year":2010,"finding":"CBX7 recruits the H3K9 methyltransferase SUV39H2 to the p16 promoter, initiating H3K9me3 formation; chromodomain mutations or Pc-box deletion abolished CBX7 binding and H3K9me3 formation; CBX7–SUV39H2 complexes were detected in the nucleus by bimolecular fluorescence complementation.","method":"ChIP (CBX7, SUV39H2, H3K9me3 at p16 locus), BiFC (CBX7–SUV39H2 nuclear complex), chromodomain/Pc-box mutants, siRNA knockdown of Suv39h2","journal":"PloS one","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — multiple orthogonal methods (ChIP, BiFC, mutagenesis, siRNA) in single lab","pmids":["21060834"],"is_preprint":false},{"year":2012,"finding":"CBX7 is necessary for recruitment of Ring1B to chromatin in ESCs; Cbx7-containing PRC1 complexes primarily control early-lineage commitment whereas RYBP-containing PRC1 complexes regulate metabolism and cell-cycle progression. Cbx7 is the primary Polycomb ortholog of PRC1 in ESCs and directly represses Cbx2, Cbx4, and Cbx8.","method":"ChIP-seq (genomic localization), Cbx7 knockdown (Ring1B chromatin recruitment), reporter assays, ESC differentiation assays","journal":"Cell reports","confidence":"High","confidence_rationale":"Tier 2 / Strong — genome-wide ChIP-seq plus functional KD with defined mechanistic readout, replicated across two papers (PMID:23273917, PMID:22226354)","pmids":["23273917","22226354"],"is_preprint":false},{"year":2012,"finding":"Cbx7 knockout mice develop liver and lung adenomas and carcinomas; Cbx7 null MEFs show increased proliferation and reduced senescence; CBX7 binds the CCNE1 (cyclin E) promoter in a complex containing HDAC2 and negatively regulates CCNE1 expression.","method":"Cbx7 knockout mouse generation, ChIP (CBX7 and HDAC2 at CCNE1 promoter), Western blot, MEF proliferation/senescence assays, human tumor tissue correlation","journal":"The Journal of clinical investigation","confidence":"High","confidence_rationale":"Tier 1–2 / Strong — in vivo KO phenotype combined with ChIP demonstrating direct promoter occupancy and co-repressor complex, orthogonal validation in human tumors","pmids":["22214847"],"is_preprint":false},{"year":2013,"finding":"MAPK signaling phosphorylates Cbx7 at Thr-118 (near the Polycomb box); a site-specific antibody confirms this phosphorylation in mammary carcinoma cells blocked by MEK inhibitors; upon EGF stimulation, phosphorylated Cbx7 interacts more robustly with other PRC1 members; Thr-118 phosphorylation moderately enhances repression of the p16 target gene in RAS-induced senescence.","method":"Mass spectrometry identification of phosphorylation site, site-specific antibody generation, MEK inhibitor treatment, EGF stimulation + Co-IP with PRC1 members, p16 repression assay with phosphomimetic mutant","journal":"The Journal of biological chemistry","confidence":"Medium","confidence_rationale":"Tier 1–2 / Moderate — biochemical and MS identification of PTM site plus functional mutagenesis in senescence model, single lab","pmids":["24194518"],"is_preprint":false},{"year":2014,"finding":"CBX7 inhibits Wnt/β-catenin signaling in breast epithelial cells by enhancing transcription of DKK-1 (a Wnt antagonist) through cooperation with p300 acetyltransferase and increased histone acetylation at the DKK-1 promoter; DKK-1 pharmacological inhibition in CBX7-overexpressing cells rescues Wnt signaling and the CD44+/CD24-/ESA+ stem-like cell population.","method":"ChIP (CBX7 and p300 at DKK-1 promoter, histone acetylation), shRNA knockdown and overexpression, pharmacological DKK-1 inhibition, stem-cell population assays","journal":"FASEB journal","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — ChIP evidence for direct promoter occupancy and co-activator interaction, functional rescue experiment, single lab","pmids":["25351982"],"is_preprint":false},{"year":2014,"finding":"CBX7 negatively or positively regulates several cancer-relevant genes (e.g., SPP1/osteopontin repressed; FOS/FOSB/EGR1 activated) by interacting with their promoter regions and modulating transcriptional activity, as shown by ChIP and gene expression profiling after CBX7 restoration.","method":"Gene expression profiling after CBX7 restoration, ChIP at gene promoters, qRT-PCR correlation in human thyroid and lung carcinoma tissues","journal":"PloS one","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — ChIP plus expression profiling plus tissue correlation, single lab","pmids":["24865347"],"is_preprint":false},{"year":2015,"finding":"Crystal structures of CBX7 chromodomain with small-molecule inhibitors reveal the binding modes; inhibitors compete with H3K27me3 peptide binding through interactions with key residues in the methyl-lysine binding aromatic cage; lead compound MS37452 displaces CBX7 from the INK4A/ARF locus and derepresses p16/CDKN2A transcription in prostate cancer cells.","method":"X-ray crystallography of CBX7ChD–inhibitor complexes, fluorescence polarization binding assays, ChIP (CBX7 displacement from INK4A/ARF locus), gene expression assays in PC3 cells","journal":"Chemistry & biology","confidence":"High","confidence_rationale":"Tier 1 / Moderate — crystal structures plus cellular functional validation, multiple orthogonal methods, single lab","pmids":["25660273"],"is_preprint":false},{"year":2016,"finding":"By live-cell single-molecule tracking, Cbx7 requires co-recognition of both H3K27me3 and DNA for chromatin targeting; the chromodomain (CD) and AT-hook-like (ATL) motif constitute a functional DNA-binding unit; H3K27me3 contributes significantly to Cbx7 and Cbx8 chromatin targeting but less to Cbx2, Cbx4, Cbx6; disruption of PRC1 complex formation facilitates Cbx7 chromatin targeting.","method":"Live-cell single-molecule tracking (SMT), CRISPR genetic engineering of H3K27me3 pathway, biochemical DNA-binding assays, Cbx7 CD and ATL mutants","journal":"eLife","confidence":"High","confidence_rationale":"Tier 1–2 / Strong — single-molecule live-cell imaging combined with genetic disruption and biochemical assays, multiple orthogonal methods","pmids":["27723458"],"is_preprint":false},{"year":2016,"finding":"Structure-guided discovery of Class B antagonist MS351, which inhibits H3K27me3 binding when CBX7ChD is bound to RNA; crystal structure of CBX7ChD/MS351 reveals ligand recognition by aromatic cage residues; MS351 induces derepression of CBX7 target genes including p16 in mESCs and PC3 cells.","method":"X-ray crystallography of CBX7ChD/MS351 complex, fluorescence polarization assays, gene expression assays (p16 derepression in mESC and PC3)","journal":"ACS medicinal chemistry letters","confidence":"High","confidence_rationale":"Tier 1 / Moderate — crystal structure plus functional cellular validation, multiple orthogonal methods, single lab","pmids":["27326334"],"is_preprint":false},{"year":2017,"finding":"dCLIP reveals that CBX7 predominantly binds 3' UTRs of mRNAs with a median footprint of ~171–183 nucleotides; four families of consensus RNA motifs were identified and their mutation abolishes CBX7 binding in vitro; antisense oligonucleotide intervention paradoxically increases CBX7 binding and enhances gene expression.","method":"Denaturing CLIP (dCLIP) in mouse and human cells, bioinformatic motif analysis, in vitro RNA binding with motif-mutant constructs, antisense oligonucleotide pharmacological intervention","journal":"Cell systems","confidence":"High","confidence_rationale":"Tier 1–2 / Strong — dCLIP in two species with motif mutagenesis and in vitro validation, multiple orthogonal methods","pmids":["29073373"],"is_preprint":false},{"year":2017,"finding":"CBX7 positively regulates miR-155 expression in MEFs and colon carcinomas, and miR-155 in turn targets KRAS protein levels; Cbx7-null MEFs show downregulation of miR-155 and corresponding upregulation of KRAS protein.","method":"miRNA microarray of Cbx7-null vs. WT MEFs, qRT-PCR validation, miR-155 transfection with Western blot for KRAS, human colon carcinoma tissue correlation","journal":"BMC cancer","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — KO model plus miRNA array plus functional transfection and target validation, single lab","pmids":["28259135"],"is_preprint":false},{"year":2018,"finding":"CBX7 represses YAP/TAZ-dependent transcription in glioblastoma; CBX7 overexpression represses CTGF (a YAP/TAZ target) and reduces phospho-JNK; CBX7 fails to inhibit glioma cell migration when CTGF is exogenously overexpressed or constitutively active JNK is present, placing CBX7 upstream of the YAP/TAZ-CTGF-JNK axis.","method":"Exogenous CBX7 overexpression, GSEA of CBX7-regulated genes identifying YAP/TAZ targets, Western blot (CTGF, p-JNK), genetic rescue experiments (CTGF OE, CA-JNK), migration assays","journal":"Scientific reports","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — epistasis by genetic rescue, GSEA pathway placement, single lab","pmids":["27291091"],"is_preprint":false},{"year":2019,"finding":"CBX7 interacts with non-histone proteins bearing trimethylated lysine peptide motifs similar to H3K27me3: the H3K9 methyltransferases SETDB1, EHMT1, and EHMT2 were identified as CBX7-binding proteins by mass spectrometry; depletion of SETDB1 in AML cells phenocopied CBX7 repression.","method":"Mass spectrometry of CBX7-associated proteins, Co-IP validation, SETDB1 knockdown phenocopy assay in AML cells, xenotransplantation of CBX7-overexpressing HSPCs","journal":"Cell reports","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — MS-based interactome with functional phenocopy validation, single lab","pmids":["30759399"],"is_preprint":false},{"year":2019,"finding":"A positive allosteric modulator (PAM) peptidomimetic UNC4976 simultaneously antagonizes H3K27me3-specific recruitment of CBX7 to target genes while increasing non-specific DNA/RNA binding, re-equilibrating PRC1 away from H3K27me3 target regions; this was demonstrated across three orthogonal cellular assays.","method":"Quantitative cellular CBX7 chromodomain assay, ChIP (target gene displacement), fluorescence polarization, cellular reporter assays","journal":"Cell chemical biology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — three orthogonal cellular assays plus mechanistic ChIP, single lab","pmids":["31422906"],"is_preprint":false},{"year":2020,"finding":"CBX7 binds directly to the E-box element to preclude TWIST-1 from binding its E-box in secondary ovarian cancer cells; deletion of CBX7 reactivates TWIST-1-induced transcription and promotes mesenchymal transformation and enhanced tumorigenicity in vivo.","method":"CBX7 deletion (CRISPR/genetic), reporter assays for TWIST-1 transcriptional activity at E-box, in vivo tumorigenicity assays","journal":"Oncogene","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — genetic deletion with direct transcriptional readout and in vivo validation, single lab","pmids":["32205869"],"is_preprint":false},{"year":2020,"finding":"The two CBX7 isoforms p36CBX7 and p22CBX7 exhibit distinct subcellular localization and opposing proliferative functions: p36CBX7 localizes to the nucleus and is expressed in proliferating cells, while p22CBX7 localizes to the cytoplasm, is induced by serum starvation, and inhibits cell proliferation.","method":"Isoform identification by molecular cloning, subcellular fractionation, immunofluorescence, serum starvation experiments, proliferation assays","journal":"Scientific reports","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — direct localization by fractionation/immunofluorescence with functional proliferation consequence, single lab","pmids":["32415167"],"is_preprint":false},{"year":2021,"finding":"CBX7 transcriptionally suppresses AKR1B10 in a PRC1-dependent manner (identified by RNA-seq and ChIP); AKR1B10 downregulation by CBX7 inactivates ERK signaling, establishing a CBX7/AKR1B10/ERK signaling axis in urinary bladder cancer.","method":"RNA-seq after CBX7 manipulation, ChIP assay at AKR1B10 locus, siRNA knockdown of AKR1B10, ERK signaling Western blot, xenograft tumor models","journal":"Cell death & disease","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — RNA-seq plus ChIP plus genetic rescue in a defined signaling axis, single lab","pmids":["34035231"],"is_preprint":false},{"year":2021,"finding":"CBX7 transcriptionally suppresses PDE4B at the transcription level in a PRC1-dependent manner in bladder cancer cells, as demonstrated by ChIP and luciferase assays.","method":"ChIP (CBX7 at PDE4B promoter), luciferase reporter assay, CBX7 knockdown/overexpression with PDE4B expression readout","journal":"Frontiers in cell and developmental biology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — ChIP plus reporter assay demonstrating direct transcriptional repression, single lab","pmids":["34977026"],"is_preprint":false},{"year":2022,"finding":"RNF26 promotes ubiquitin-mediated proteasomal degradation of CBX7 in clear cell renal cell carcinoma; RNF26 knockdown reduces CBX7 ubiquitination, stabilizes CBX7 protein, and inhibits tumor growth, establishing RNF26 as a CBX7 E3 ubiquitin ligase.","method":"Co-IP (RNF26–CBX7 interaction), ubiquitination assay, cycloheximide chase (protein stability), RNF26 KD/OE with CBX7 protein level readout, xenograft models","journal":"International journal of biological sciences","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — ubiquitination assay plus stability chase plus Co-IP, single lab","pmids":["35342353"],"is_preprint":false},{"year":2022,"finding":"EZH2 represses CBX7 expression by increasing H3K27me3 at the CBX7 promoter in bladder cancer cells; CBX7 in turn directly downregulates FGFR3 expression (shown by ChIP-qPCR) and sensitizes bladder cancer cells to cisplatin by inactivating PI3K-AKT signaling.","method":"ChIP-qPCR (H3K27me3 at CBX7 promoter; CBX7 at FGFR3 promoter), RT-qPCR, Western blot, CCK-8 cisplatin sensitivity assay, xenograft mouse model","journal":"British journal of cancer","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — ChIP-qPCR showing direct promoter occupancy at two levels of the axis, xenograft validation, single lab","pmids":["36396821"],"is_preprint":false},{"year":2022,"finding":"CBX7 downregulates POU2F2 expression, which indirectly represses PD-L1 in bladder cancer cells; depletion of CBX7 results in resistance to PD-1 blockade, establishing a CBX7/POU2F2/PD-L1 regulatory axis.","method":"RNA-seq (CBX7 KD, GSE185630), Western blot/RT-qPCR (POU2F2, PD-L1), PD-1 blockade functional assay","journal":"Biochemical and biophysical research communications","confidence":"Low","confidence_rationale":"Tier 3 / Weak — pathway inferred from RNA-seq plus Western blot, indirect (POU2F2 intermediate not directly shown bound to PD-L1 promoter by CBX7), single lab","pmids":["35526483"],"is_preprint":false},{"year":2022,"finding":"Circ_0006790 facilitates nuclear translocation of CBX7; nuclear CBX7 increases DNA methylation of S100A11 by recruiting DNA methyltransferases to its promoter, thereby inhibiting S100A11 transcription and suppressing PDAC immune escape.","method":"RNA pull-down and RIP (circ_6790–CBX7 interaction), subcellular fractionation (CBX7 nuclear translocation), ChIP (DNMT recruitment to S100A11 promoter), siRNA knockdowns, xenograft assays","journal":"American journal of cancer research","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — pull-down, fractionation, ChIP, and functional rescue in a single study, single lab","pmids":["35693076"],"is_preprint":false},{"year":2023,"finding":"CBX7 interacts with TARDBP (TDP-43) and positively regulates its downstream target RBM38 in a TARDBP-dependent manner; this CBX7–TARDBP–RBM38 axis drives cardiomyocyte cell cycle exit postnatally, and Cbx7 genetic inactivation promotes cardiomyocyte proliferation and cardiac regeneration after injury.","method":"Co-immunoprecipitation + mass spectrometry (CBX7–TARDBP interaction), conditional and inducible cardiac-specific KO mice, adenoviral CBX7 overexpression, immunostaining for proliferation markers, neonatal apical resection and adult MI models","journal":"Circulation","confidence":"High","confidence_rationale":"Tier 2 / Strong — MS-identified interaction confirmed by Co-IP, genetic KO with specific proliferative phenotype, in vivo cardiac regeneration models, multiple orthogonal methods","pmids":["37158107"],"is_preprint":false},{"year":2024,"finding":"CBX7 transcriptionally inhibits USP44 expression; reduced USP44 promotes proteasome-dependent degradation of c-MYC protein, consequently attenuating c-MYC-mediated transactivation of LDHA and inhibiting glycolysis in meningioma cells.","method":"iTRAQ proteomics after CBX7 restoration, ChIP (CBX7 at USP44 promoter), luciferase reporter assay, Western blot (c-MYC stability), proteasome inhibitor experiments, xenograft mouse models","journal":"Journal of molecular cell biology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — ChIP plus reporter assay plus proteasome inhibitor rescue, iTRAQ proteomics, single lab","pmids":["37791390"],"is_preprint":false},{"year":2024,"finding":"CBX7 blocks Twist1 binding to the EphA2 promoter and inhibits EphA2 expression; loss of CBX7 allows Twist1 to transactivate EphA2, promoting BLBC metastasis via the Twist1/EphA2 axis.","method":"ChIP assay (Twist1 at EphA2 promoter with/without CBX7), dual-luciferase reporter assay, Western blot, in vitro migration/invasion assays","journal":"Translational oncology","confidence":"Low","confidence_rationale":"Tier 3 / Weak — single lab, ChIP and reporter without direct CBX7–Twist1 binding characterization","pmids":["35843065"],"is_preprint":false},{"year":2024,"finding":"RNF2 promotes ubiquitination and proteasomal degradation of CBX7 in chondrosarcoma; RNF2 knockdown reduces CBX7 ubiquitination and increases CBX7 protein stability (cycloheximide chase), without affecting CBX7 mRNA levels.","method":"Co-IP, ubiquitination assay, cycloheximide chase (protein stability), RNF2 KD/OE with CBX7 readout, xenograft mouse model","journal":"Cancer & metabolism","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — ubiquitination assay plus stability chase plus Co-IP in multiple cell systems, single lab","pmids":["39456039"],"is_preprint":false},{"year":2024,"finding":"CBX7 promotes HIF-1α transcription and nuclear translocation and transcriptional activity in choroidal vascular endothelial cells under hypoxia, which in turn stimulates VEGF transcription and promotes pro-angiogenic behaviors (migration, proliferation, tube formation) via the CBX7/HIF-1α/VEGF pathway.","method":"CBX7 knockdown/overexpression in HCVECs, Western blot (HIF-1α, VEGF), nuclear fractionation (HIF-1α translocation), functional angiogenesis assays (migration, tube formation), laser-induced CNV mouse model","journal":"Experimental eye research","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — multiple functional assays plus in vivo CNV model, single lab","pmids":["39179168"],"is_preprint":false},{"year":2024,"finding":"CBX7 interacts with H3K9 methyltransferases EHMT1/2 and SETDB1; pharmacological inhibition of CBX7 abolishes this interaction, reduces H3K9 methylation, and reactivates target gene expression; CBX7 inhibitors also affect H2Aub-mediated (Polycomb) gene repression.","method":"Co-IP (CBX7–EHMT1/2/SETDB1), pharmacological CBX7 inhibitor treatment, H3K9me and H2Aub Western blot, gene expression assays, combination drug growth assays","journal":"Experimental hematology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — Co-IP plus pharmacological perturbation plus histone modification readout, single lab","pmids":["39613290"],"is_preprint":false},{"year":2025,"finding":"DNMT1 methylates the CBX7 promoter region to repress CBX7 expression in PDAC; reduced CBX7 leads to increased ERK phosphorylation, promoting tumorigenesis and metastasis; the DNMT1/CBX7/ERK axis was confirmed by ChIP and dual-luciferase assays.","method":"ChIP (DNMT1 at CBX7 promoter), dual-luciferase reporter assay, DNMT1 knockdown with CBX7 and ERK readout, CCK-8/wound healing/transwell functional assays","journal":"FASEB journal","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — ChIP plus reporter assay plus functional rescue, single lab","pmids":["40387566"],"is_preprint":false},{"year":2026,"finding":"CBX7 forms a methylation-dependent transcriptional activation complex at cytokine gene promoters in lymphoid cells (unexpected activating role); CBX7 also translocates to the cytosol and forms a methylation-dependent signaling complex with c-Raf, MEK1/2, and CK2-α to sustain ERK1/2 signaling; these activities are lymphoid-cell specific and absent in epithelial cells.","method":"Co-IP (CBX7–c-Raf–MEK1/2–CK2α), ChIP (CBX7 at cytokine gene promoters), subcellular fractionation, genetic KO and pharmacological inhibition in mouse and human lymphoid cells, RNA-seq, allergic asthma mouse models","journal":"Science advances","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — Co-IP plus ChIP plus genetic/pharmacological intervention across multiple mouse models, single lab but multiple orthogonal methods","pmids":["41686891"],"is_preprint":false},{"year":2026,"finding":"CBX7 preferentially binds Ser31-phosphorylated H3.3K27me3 nucleosomes and recruits KAP1 (KRAB-associated protein 1); disruption of the H3.3–CBX7 interaction impairs H3K9me3 heterochromatin formation and activates retrotransposons; during X-chromosome inactivation, H3K9me2/3 fails to accumulate at the inactive X when the H3.3–CBX7–KAP1 axis is blocked.","method":"Co-IP/nucleosome pulldown (CBX7 binding to H3.3S31ph-K27me3), H3K9me3 ChIP after H3.3–CBX7 disruption, retrotransposon activation assays, X-chromosome inactivation assays","journal":"Science bulletin","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — nucleosome binding with defined modifications plus ChIP showing downstream H3K9me3 effects, single lab, functional validation in two biological contexts","pmids":["41582043"],"is_preprint":false}],"current_model":"CBX7 is a PRC1 chromodomain protein that recognizes H3K27me3 (and H3.3S31ph-K27me3) via its aromatic cage, co-recognizes DNA through an AT-hook-like motif, and binds noncoding RNAs including ANRIL and 3' UTRs of mRNAs to direct transcriptional repression of targets such as the INK4a/ARF locus, CCNE1, AKR1B10, FGFR3, and PDE4B; it recruits co-repressors including Ring1B, HDAC2, and H3K9 methyltransferases (SUV39H2, EHMT1/2, SETDB1), is itself phosphorylated at Thr-118 by MAPK signaling to modulate PRC1 interactions, and is subject to proteasomal degradation mediated by E3 ubiquitin ligases RNF26 and RNF2; in addition, CBX7 can function as a transcriptional activator and cytosolic signaling scaffold (with c-Raf, MEK1/2, CK2-α for ERK1/2 activation) specifically in lymphoid cells, and distinct isoforms localize differentially to nucleus versus cytoplasm with opposing effects on cell proliferation."},"narrative":{"mechanistic_narrative":"CBX7 is a chromodomain subunit of Polycomb repressive complex 1 (PRC1) that reads repressive chromatin marks and directs transcriptional silencing of cell-cycle and tumor-suppressor loci, most prominently the INK4a/ARF locus, to control cellular senescence and proliferative lifespan [PMID:14647293, PMID:15897876, PMID:22214847]. Chromatin targeting requires bivalent recognition: the chromodomain engages H3K27me3 — and preferentially Ser31-phosphorylated H3.3K27me3 nucleosomes — while a chromodomain–AT-hook-like (ATL) unit co-recognizes DNA, with both inputs needed for stable target binding in living cells [PMID:27723458, PMID:41582043]. The same chromodomain binds noncoding RNA, including ANRIL, and this RNA interaction acts in concert with H3K27me3 reading to enforce repression of INK4b/ARF/INK4a, while transcriptome-wide CLIP shows CBX7 footprints concentrated in mRNA 3' UTRs through defined sequence motifs [PMID:20541999, PMID:29073373]. Once recruited, CBX7 is required for Ring1B deposition on chromatin in embryonic stem cells, where it is the dominant PRC1 ortholog directing early-lineage commitment and repressing other Cbx paralogs [PMID:23273917, PMID:22226354]. CBX7 nucleates layered silencing by recruiting co-repressors: HDAC2 at the CCNE1 promoter [PMID:22214847], DNA methyltransferases at target promoters [PMID:19602592, PMID:35693076], and H3K9 methyltransferases SUV39H2, EHMT1/2 and SETDB1 to seed H3K9 methylation, the latter recognized through trimethyl-lysine motifs resembling H3K27me3 [PMID:21060834, PMID:30759399, PMID:39613290]. Through these activities CBX7 represses a broad set of oncogenic effectors — CCNE1, AKR1B10, PDE4B, FGFR3, USP44, SPP1 and the Twist1-dependent EphA2 program — thereby restraining ERK, PI3K-AKT, c-MYC/glycolysis and metastatic transcriptional outputs [PMID:22214847, PMID:34035231, PMID:34977026, PMID:36396821, PMID:37791390, PMID:32205869], while in some contexts acting as a transcriptional activator, cooperating with p300 to induce the Wnt antagonist DKK-1 and activating FOS/FOSB/EGR1 [PMID:25351982, PMID:24865347]. CBX7 activity is itself controlled post-translationally: MAPK signaling phosphorylates Thr-118 near the Polycomb box to strengthen PRC1 association, and the E3 ligases RNF26 and RNF2 drive its ubiquitin-mediated proteasomal degradation [PMID:24194518, PMID:35342353, PMID:39456039]. Distinct isoforms partition between nucleus and cytoplasm with opposing effects on proliferation, and beyond its canonical repressive role CBX7 functions in lymphoid cells as a cytosolic signaling scaffold for c-Raf/MEK1/2/CK2-α to sustain ERK1/2 activity and as a methylation-dependent transcriptional activator of cytokine genes [PMID:32415167, PMID:41686891]. CBX7 also drives a developmental cell-cycle exit program through a TARDBP/RBM38 axis that limits cardiomyocyte proliferation [PMID:37158107]. The chromodomain methyl-lysine cage is a validated small-molecule target whose inhibition or allosteric re-equilibration displaces CBX7 from target loci and derepresses p16/CDKN2A [PMID:25660273, PMID:27326334, PMID:31422906].","teleology":[{"year":2003,"claim":"Established CBX7 as a functional PRC1 component whose repression of the Ink4a/Arf locus sets cellular proliferative lifespan, defining its core biology.","evidence":"Co-IP with Ring1, Polycomb-body immunofluorescence, and shRNA knockdown with p16/Arf readout in a senescence-bypass cDNA screen","pmids":["14647293"],"confidence":"High","gaps":["Did not resolve how CBX7 selects the INK4a/ARF locus","Co-repressor machinery downstream of Ring1 not yet defined"]},{"year":2005,"claim":"Extended INK4a/ARF repression to human prostate cells and showed the growth phenotype depends on intact p16/Rb and p14ARF/p53 pathways.","evidence":"shRNA knockdown with Western blot and growth assays in LNCaP and PC-3 cells","pmids":["15897876"],"confidence":"Medium","gaps":["Direct promoter occupancy not shown in this study","Limited to two cell lines from one lab"]},{"year":2007,"claim":"Placed CBX7 genetically upstream of the Arf-p53 axis in vivo, demonstrating oncogenic cooperation with c-Myc during lymphomagenesis.","evidence":"Lymphoid-targeted Cbx7 transgenic mice with genetic epistasis and tumor characterization","pmids":["17374722"],"confidence":"High","gaps":["Molecular basis of c-Myc cooperation not defined","Targets beyond Ink4a/Arf in lymphoma not identified"]},{"year":2009,"claim":"Connected CBX7 to DNA methylation by showing it associates with DNMTs and can seed promoter hypermethylation, linking Polycomb repression to a heritable silencing layer.","evidence":"Co-IP and ChIP for DNMT assembly at CBX7 targets with gain/loss in embryonal carcinoma cells","pmids":["19602592"],"confidence":"Medium","gaps":["Direct vs. indirect DNMT recruitment unresolved","Single lab, single cell context"]},{"year":2010,"claim":"Defined the chromodomain as a dual H3K27me3- and RNA-reader, showing ANRIL binding is required for INK4 locus repression and revealing the structural interplay between the two ligands.","evidence":"RNA-IP, NMR of chromodomain–RNA interaction, separation-of-function chromodomain mutants, ChIP and senescence assays","pmids":["20541999"],"confidence":"High","gaps":["How RNA and H3K27me3 binding are coordinated kinetically not resolved","Generality beyond ANRIL not addressed here"]},{"year":2010,"claim":"Demonstrated CBX7 recruits the H3K9 methyltransferase SUV39H2 to seed H3K9me3, coupling Polycomb to H3K9 methylation in cis.","evidence":"ChIP for CBX7/SUV39H2/H3K9me3 at p16, BiFC, and chromodomain/Pc-box mutants with siRNA","pmids":["21060834"],"confidence":"Medium","gaps":["Direct SUV39H2 contact surface not mapped","Restricted to the p16 locus"]},{"year":2012,"claim":"Showed CBX7 is required for Ring1B chromatin recruitment in ESCs and is the dominant PRC1 ortholog controlling early lineage commitment and Cbx paralog repression.","evidence":"ChIP-seq, Cbx7 knockdown with Ring1B recruitment readout, reporter and differentiation assays (two papers)","pmids":["23273917","22226354"],"confidence":"High","gaps":["Mechanism distinguishing Cbx7- vs RYBP-PRC1 targeting not fully defined","Stoichiometry within PRC1 not measured"]},{"year":2012,"claim":"An in vivo knockout established CBX7 as a tumor suppressor and identified CCNE1 as a direct target repressed via an HDAC2-containing complex.","evidence":"Cbx7 KO mice with tumor phenotype, MEF senescence assays, ChIP for CBX7/HDAC2 at CCNE1, human tumor correlation","pmids":["22214847"],"confidence":"High","gaps":["HDAC2 recruitment mechanism not defined","Full target set behind the KO phenotype unknown"]},{"year":2013,"claim":"Identified Thr-118 phosphorylation by MAPK signaling as a switch that strengthens CBX7–PRC1 association, linking upstream kinase signaling to Polycomb function.","evidence":"Mass spectrometry site mapping, phospho-specific antibody, MEK inhibitor and EGF stimulation with Co-IP, phosphomimetic p16 repression assay","pmids":["24194518"],"confidence":"Medium","gaps":["Magnitude of functional effect modest","Responsible kinase not directly identified"]},{"year":2014,"claim":"Revealed a transcriptional-activator mode in which CBX7 cooperates with p300 to induce DKK-1 and restrain Wnt/β-catenin signaling and stem-like populations.","evidence":"ChIP for CBX7/p300 and acetylation at DKK-1, knockdown/overexpression, pharmacological DKK-1 inhibition rescue","pmids":["25351982"],"confidence":"Medium","gaps":["How CBX7 switches between repressor and activator modes unknown","Single lab"]},{"year":2014,"claim":"Broadened the CBX7 regulon to include both repressed (SPP1) and activated (FOS/FOSB/EGR1) genes via direct promoter occupancy.","evidence":"Expression profiling after CBX7 restoration, ChIP at promoters, tissue correlation in thyroid and lung carcinoma","pmids":["24865347"],"confidence":"Medium","gaps":["Determinants of activation vs repression at each promoter unresolved"]},{"year":2015,"claim":"Provided crystal structures of the chromodomain with inhibitors that compete with H3K27me3 and pharmacologically derepress p16, validating the methyl-lysine cage as a druggable target.","evidence":"X-ray crystallography, fluorescence polarization, ChIP displacement and expression in PC3 cells (MS37452)","pmids":["25660273"],"confidence":"High","gaps":["Inhibitor selectivity across CBX paralogs not fully resolved"]},{"year":2016,"claim":"Live-cell single-molecule tracking showed CBX7 requires combinatorial H3K27me3 and DNA co-recognition via a chromodomain–ATL unit for chromatin targeting.","evidence":"Single-molecule tracking, CRISPR disruption of the H3K27me3 pathway, biochemical DNA-binding assays, CD/ATL mutants","pmids":["27723458"],"confidence":"High","gaps":["Sequence specificity of the DNA-binding unit not defined","Interplay with RNA binding during targeting unresolved"]},{"year":2016,"claim":"Discovered a Class B antagonist (MS351) that selectively blocks H3K27me3 binding when the chromodomain is RNA-bound, dissecting the RNA-versus-histone reading states pharmacologically.","evidence":"Crystal structure of CBX7ChD/MS351, fluorescence polarization, p16 derepression in mESC and PC3","pmids":["27326334"],"confidence":"High","gaps":["In vivo efficacy not established","Selectivity profile limited"]},{"year":2017,"claim":"Transcriptome-wide CLIP defined CBX7 as an mRNA 3' UTR binder with discrete sequence motifs, expanding its RNA interactome beyond ANRIL.","evidence":"dCLIP in mouse and human cells, motif analysis, in vitro binding with motif mutants, antisense oligonucleotide intervention","pmids":["29073373"],"confidence":"High","gaps":["Functional consequence of 3' UTR binding on each transcript unclear","Link between cytoplasmic RNA binding and chromatin role unresolved"]},{"year":2017,"claim":"Linked CBX7 to KRAS control via positive regulation of miR-155, illustrating an indirect post-transcriptional output.","evidence":"miRNA microarray in Cbx7-null vs WT MEFs, miR-155 transfection with KRAS Western blot, colon carcinoma tissue correlation","pmids":["28259135"],"confidence":"Medium","gaps":["Mechanism of miR-155 promoter regulation by CBX7 not shown","Single lab"]},{"year":2018,"claim":"Positioned CBX7 upstream of a YAP/TAZ–CTGF–JNK axis to restrain glioma migration.","evidence":"Overexpression, GSEA, Western blot for CTGF/p-JNK, genetic rescue (CTGF OE, CA-JNK), migration assays","pmids":["27291091"],"confidence":"Medium","gaps":["Direct promoter targets in the axis not mapped","Single lab"]},{"year":2019,"claim":"Identified the H3K9 methyltransferases SETDB1, EHMT1 and EHMT2 as CBX7 partners recognized through trimethyl-lysine motifs, extending chromodomain reading to non-histone methylated proteins.","evidence":"Mass spectrometry interactome, Co-IP, SETDB1 knockdown phenocopy in AML cells, HSPC xenotransplant","pmids":["30759399"],"confidence":"Medium","gaps":["Direct vs bridged interactions not all resolved","Single lab"]},{"year":2019,"claim":"Characterized a positive allosteric modulator (UNC4976) that re-equilibrates PRC1 off H3K27me3 targets by enhancing non-specific nucleic-acid binding, refining the pharmacological model.","evidence":"Quantitative cellular chromodomain assay, ChIP displacement, fluorescence polarization, reporter assays","pmids":["31422906"],"confidence":"Medium","gaps":["In vivo relevance not tested","Single lab"]},{"year":2020,"claim":"Showed CBX7 directly occludes the E-box to block TWIST-1-driven mesenchymal transformation in ovarian cancer.","evidence":"CRISPR/genetic CBX7 deletion, E-box reporter assays, in vivo tumorigenicity","pmids":["32205869"],"confidence":"Medium","gaps":["Direct CBX7–DNA contact at the E-box not structurally characterized","Single lab"]},{"year":2020,"claim":"Established that two CBX7 isoforms partition between nucleus and cytoplasm with opposing proliferative functions, indicating isoform-resolved biology.","evidence":"Molecular cloning, subcellular fractionation, immunofluorescence, serum starvation and proliferation assays","pmids":["32415167"],"confidence":"Medium","gaps":["Molecular basis of cytoplasmic p22CBX7 anti-proliferative effect unknown","Single lab"]},{"year":2021,"claim":"Defined a CBX7/AKR1B10/ERK repressive axis in bladder cancer through PRC1-dependent transcriptional silencing.","evidence":"RNA-seq, ChIP at AKR1B10, siRNA rescue, ERK Western blot, xenografts","pmids":["34035231"],"confidence":"Medium","gaps":["How AKR1B10 controls ERK not mechanistically resolved","Single lab"]},{"year":2021,"claim":"Identified PDE4B as another directly repressed PRC1-dependent CBX7 target in bladder cancer.","evidence":"ChIP at PDE4B promoter, luciferase reporter, knockdown/overexpression","pmids":["34977026"],"confidence":"Medium","gaps":["Downstream signaling consequence not detailed here","Single lab"]},{"year":2022,"claim":"Established RNF26 as an E3 ligase driving ubiquitin-dependent CBX7 degradation, defining a route for CBX7 protein turnover in renal cancer.","evidence":"Co-IP, ubiquitination assay, cycloheximide chase, RNF26 KD/OE, xenografts","pmids":["35342353"],"confidence":"Medium","gaps":["Ubiquitination site on CBX7 not mapped","Single lab"]},{"year":2022,"claim":"Placed CBX7 in an EZH2-repressed feedback loop and showed CBX7 represses FGFR3 to sensitize bladder cancer to cisplatin via PI3K-AKT inactivation.","evidence":"ChIP-qPCR at CBX7 and FGFR3 promoters, RT-qPCR/Western blot, cisplatin sensitivity assay, xenograft","pmids":["36396821"],"confidence":"Medium","gaps":["Direct vs indirect PI3K-AKT modulation not separated","Single lab"]},{"year":2022,"claim":"Linked CBX7 to immune evasion through a CBX7/POU2F2/PD-L1 axis governing PD-1 blockade response.","evidence":"RNA-seq, Western blot/RT-qPCR for POU2F2 and PD-L1, PD-1 blockade functional assay","pmids":["35526483"],"confidence":"Low","gaps":["POU2F2 intermediate to PD-L1 not directly demonstrated at the promoter — indirect inference","Single lab"]},{"year":2022,"claim":"Showed circ_0006790 promotes CBX7 nuclear translocation enabling DNMT-mediated S100A11 silencing to suppress pancreatic cancer immune escape.","evidence":"RNA pull-down/RIP, fractionation, ChIP for DNMT at S100A11, siRNA knockdowns, xenografts","pmids":["35693076"],"confidence":"Medium","gaps":["How circRNA controls CBX7 trafficking mechanistically unclear","Single lab"]},{"year":2023,"claim":"Defined a CBX7–TARDBP–RBM38 axis driving postnatal cardiomyocyte cell-cycle exit, revealing a developmental, non-canonical CBX7 program.","evidence":"Co-IP/MS for CBX7–TARDBP, cardiac-specific KO mice, adenoviral overexpression, proliferation immunostaining, injury/regeneration models","pmids":["37158107"],"confidence":"High","gaps":["Whether this axis is PRC1-dependent unresolved","Direct RBM38 regulation mechanism not fully mapped"]},{"year":2024,"claim":"Connected CBX7 to metabolic control by showing it represses USP44, destabilizing c-MYC and reducing LDHA-driven glycolysis in meningioma.","evidence":"iTRAQ proteomics, ChIP at USP44, luciferase reporter, c-MYC stability and proteasome inhibitor assays, xenografts","pmids":["37791390"],"confidence":"Medium","gaps":["Direct USP44–c-MYC deubiquitination step inferred not proven here","Single lab"]},{"year":2024,"claim":"Showed CBX7 blocks Twist1 access to the EphA2 promoter to suppress basal-like breast cancer metastasis.","evidence":"ChIP for Twist1 at EphA2 with/without CBX7, dual-luciferase, migration/invasion assays","pmids":["35843065"],"confidence":"Low","gaps":["Direct CBX7–Twist1 binding not characterized — competitive mechanism inferred","Single lab"]},{"year":2024,"claim":"Identified RNF2 as a second E3 ligase degrading CBX7 in chondrosarcoma, reinforcing ubiquitin-proteasomal control of CBX7 abundance.","evidence":"Co-IP, ubiquitination assay, cycloheximide chase, RNF2 KD/OE, xenograft","pmids":["39456039"],"confidence":"Medium","gaps":["Relationship between RNF2 and RNF26 in CBX7 turnover unknown","Single lab"]},{"year":2024,"claim":"Revealed a pro-angiogenic CBX7/HIF-1α/VEGF program under hypoxia, an activating role in vascular endothelial cells.","evidence":"Knockdown/overexpression in HCVECs, Western blot, nuclear fractionation, angiogenesis assays, laser-induced CNV mouse model","pmids":["39179168"],"confidence":"Medium","gaps":["Direct vs indirect HIF-1α transcriptional control unresolved","Single lab"]},{"year":2024,"claim":"Confirmed CBX7 partnering with EHMT1/2 and SETDB1 and showed CBX7 inhibitors disrupt these interactions, lowering H3K9 methylation and affecting H2Aub-mediated repression.","evidence":"Co-IP, pharmacological CBX7 inhibition, H3K9me and H2Aub Western blot, expression and combination growth assays","pmids":["39613290"],"confidence":"Medium","gaps":["Whether H3K9-MTase recruitment is direct or PRC1-bridged not resolved","Single lab"]},{"year":2025,"claim":"Placed CBX7 in a DNMT1/CBX7/ERK axis in pancreatic cancer, where promoter methylation silences CBX7 to relieve ERK suppression.","evidence":"ChIP for DNMT1 at CBX7 promoter, dual-luciferase, DNMT1 knockdown with CBX7/ERK readout, functional assays","pmids":["40387566"],"confidence":"Medium","gaps":["How CBX7 restrains ERK mechanistically not defined","Single lab"]},{"year":2026,"claim":"Uncovered a lymphoid-specific, non-canonical CBX7: a cytosolic c-Raf/MEK1/2/CK2-α signaling scaffold sustaining ERK1/2 and a methylation-dependent transcriptional activator of cytokine genes.","evidence":"Co-IP, ChIP at cytokine promoters, fractionation, genetic KO and pharmacological inhibition in mouse/human lymphoid cells, RNA-seq, asthma models","pmids":["41686891"],"confidence":"Medium","gaps":["Molecular basis of cell-type specificity unknown","How a Polycomb reader scaffolds cytosolic kinases not structurally defined"]},{"year":2026,"claim":"Showed CBX7 preferentially reads Ser31-phosphorylated H3.3K27me3 and recruits KAP1 to build H3K9me3 heterochromatin, controlling retrotransposon silencing and X-inactivation.","evidence":"Nucleosome pulldown with defined modifications, H3K9me3 ChIP after disruption, retrotransposon and X-inactivation assays","pmids":["41582043"],"confidence":"Medium","gaps":["Structural basis of S31ph-K27me3 preference not solved","Direct CBX7–KAP1 contact surface unmapped"]},{"year":null,"claim":"How CBX7 chooses between its repressor, activator, and cytosolic-scaffold modes — and how RNA, DNA, and methyl-lysine reading are integrated to determine context-specific output — remains unresolved.","evidence":"","pmids":[],"confidence":"Medium","gaps":["No unifying model linking nuclear/cytoplasmic isoforms, lymphoid scaffold function, and PRC1 repression","Determinants of activator vs repressor outcome at individual promoters undefined","Integration of 3' UTR mRNA binding with chromatin role unknown"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0042393","term_label":"histone binding","supporting_discovery_ids":[1,12,35]},{"term_id":"GO:0003723","term_label":"RNA binding","supporting_discovery_ids":[1,14]},{"term_id":"GO:0003677","term_label":"DNA binding","supporting_discovery_ids":[12,19]},{"term_id":"GO:0140110","term_label":"transcription regulator activity","supporting_discovery_ids":[0,7,9,10]},{"term_id":"GO:0060090","term_label":"molecular adaptor activity","supporting_discovery_ids":[0,5,6,34]}],"localization":[{"term_id":"GO:0005634","term_label":"nucleus","supporting_discovery_ids":[0,20]},{"term_id":"GO:0005829","term_label":"cytosol","supporting_discovery_ids":[20,34]},{"term_id":"GO:0000228","term_label":"nuclear chromosome","supporting_discovery_ids":[35]}],"pathway":[{"term_id":"R-HSA-4839726","term_label":"Chromatin organization","supporting_discovery_ids":[0,6,35]},{"term_id":"R-HSA-74160","term_label":"Gene expression (Transcription)","supporting_discovery_ids":[7,10,21,22]},{"term_id":"R-HSA-1640170","term_label":"Cell Cycle","supporting_discovery_ids":[0,7,27]},{"term_id":"R-HSA-1643685","term_label":"Disease","supporting_discovery_ids":[3,7,24]},{"term_id":"R-HSA-162582","term_label":"Signal Transduction","supporting_discovery_ids":[16,21,34]}],"complexes":["PRC1"],"partners":["RING1","RNF2","HDAC2","SUV39H2","SETDB1","EHMT1","TARDBP","KAP1"],"other_free_text":[]}},"prefetch_data":{"uniprot":{"accession":"O95931","full_name":"Chromobox protein homolog 7","aliases":[],"length_aa":251,"mass_kda":28.3,"function":"Component of a Polycomb group (PcG) multiprotein PRC1-like complex, a complex class required to maintain the transcriptionally repressive state of many genes, including Hox genes, throughout development. PcG PRC1 complex acts via chromatin remodeling and modification of histones; it mediates monoubiquitination of histone H2A 'Lys-119', rendering chromatin heritably changed in its expressibility. Promotes histone H3 trimethylation at 'Lys-9' (H3K9me3). Binds to trimethylated lysine residues in histones, and possibly also other proteins. Regulator of cellular lifespan by maintaining the repression of CDKN2A, but not by inducing telomerase activity","subcellular_location":"Nucleus","url":"https://www.uniprot.org/uniprotkb/O95931/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/CBX7","classification":"Not Classified","n_dependent_lines":7,"n_total_lines":1208,"dependency_fraction":0.005794701986754967},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[],"url":"https://opencell.sf.czbiohub.org/search/CBX7","total_profiled":1310},"omim":[{"mim_id":"617438","title":"CHROMOBOX 6; CBX6","url":"https://www.omim.org/entry/617438"},{"mim_id":"608457","title":"CHROMOBOX 7; CBX7","url":"https://www.omim.org/entry/608457"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"Supported","locations":[{"location":"Nucleoplasm","reliability":"Supported"},{"location":"Cytosol","reliability":"Additional"}],"tissue_specificity":"Low tissue specificity","tissue_distribution":"Detected in all","driving_tissues":[],"url":"https://www.proteinatlas.org/search/CBX7"},"hgnc":{"alias_symbol":[],"prev_symbol":[]},"alphafold":{"accession":"O95931","domains":[{"cath_id":"2.40.50.40","chopping":"12-71","consensus_level":"high","plddt":92.2798,"start":12,"end":71}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/O95931","model_url":"https://alphafold.ebi.ac.uk/files/AF-O95931-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-O95931-F1-predicted_aligned_error_v6.png","plddt_mean":66.25},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=CBX7","jax_strain_url":"https://www.jax.org/strain/search?query=CBX7"},"sequence":{"accession":"O95931","fasta_url":"https://rest.uniprot.org/uniprotkb/O95931.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/O95931/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/O95931"}},"corpus_meta":[{"pmid":"20541999","id":"PMC_20541999","title":"Molecular interplay of the noncoding RNA ANRIL and methylated histone H3 lysine 27 by polycomb CBX7 in transcriptional silencing of INK4a.","date":"2010","source":"Molecular cell","url":"https://pubmed.ncbi.nlm.nih.gov/20541999","citation_count":1131,"is_preprint":false},{"pmid":"14647293","id":"PMC_14647293","title":"Polycomb CBX7 has a unifying role in cellular lifespan.","date":"2003","source":"Nature cell biology","url":"https://pubmed.ncbi.nlm.nih.gov/14647293","citation_count":265,"is_preprint":false},{"pmid":"22226354","id":"PMC_22226354","title":"MicroRNA regulation of Cbx7 mediates a switch of Polycomb orthologs during ESC differentiation.","date":"2012","source":"Cell stem cell","url":"https://pubmed.ncbi.nlm.nih.gov/22226354","citation_count":170,"is_preprint":false},{"pmid":"23273917","id":"PMC_23273917","title":"RYBP and Cbx7 define specific biological functions of polycomb complexes in mouse embryonic stem cells.","date":"2012","source":"Cell reports","url":"https://pubmed.ncbi.nlm.nih.gov/23273917","citation_count":169,"is_preprint":false},{"pmid":"17374722","id":"PMC_17374722","title":"Role of the chromobox protein CBX7 in lymphomagenesis.","date":"2007","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/17374722","citation_count":142,"is_preprint":false},{"pmid":"22214847","id":"PMC_22214847","title":"CBX7 is a tumor suppressor in mice and humans.","date":"2012","source":"The Journal of clinical investigation","url":"https://pubmed.ncbi.nlm.nih.gov/22214847","citation_count":126,"is_preprint":false},{"pmid":"15897876","id":"PMC_15897876","title":"CBX7 controls the growth of normal and tumor-derived prostate cells by repressing the Ink4a/Arf locus.","date":"2005","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/15897876","citation_count":122,"is_preprint":false},{"pmid":"25660273","id":"PMC_25660273","title":"Small-molecule modulators of methyl-lysine binding for the CBX7 chromodomain.","date":"2015","source":"Chemistry & biology","url":"https://pubmed.ncbi.nlm.nih.gov/25660273","citation_count":100,"is_preprint":false},{"pmid":"27723458","id":"PMC_27723458","title":"Live-cell single-molecule tracking reveals co-recognition of H3K27me3 and DNA targets polycomb Cbx7-PRC1 to chromatin.","date":"2016","source":"eLife","url":"https://pubmed.ncbi.nlm.nih.gov/27723458","citation_count":97,"is_preprint":false},{"pmid":"29422082","id":"PMC_29422082","title":"CBX7 regulates stem cell-like properties of gastric cancer cells via p16 and AKT-NF-κB-miR-21 pathways.","date":"2018","source":"Journal of hematology & oncology","url":"https://pubmed.ncbi.nlm.nih.gov/29422082","citation_count":94,"is_preprint":false},{"pmid":"24625057","id":"PMC_24625057","title":"Chromodomain antagonists that target the polycomb-group methyllysine reader protein chromobox homolog 7 (CBX7).","date":"2014","source":"Journal of medicinal chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/24625057","citation_count":80,"is_preprint":false},{"pmid":"21779448","id":"PMC_21779448","title":"Identification of a New Pathway for Tumor Progression: MicroRNA-181b Up-Regulation and CBX7 Down-Regulation by HMGA1 Protein.","date":"2010","source":"Genes & cancer","url":"https://pubmed.ncbi.nlm.nih.gov/21779448","citation_count":69,"is_preprint":false},{"pmid":"25351982","id":"PMC_25351982","title":"CBX7 inhibits breast tumorigenicity through DKK-1-mediated suppression of the Wnt/β-catenin pathway.","date":"2014","source":"FASEB journal : official publication of the Federation of American Societies for Experimental Biology","url":"https://pubmed.ncbi.nlm.nih.gov/25351982","citation_count":63,"is_preprint":false},{"pmid":"19602592","id":"PMC_19602592","title":"Polycomb CBX7 promotes initiation of heritable repression of genes frequently silenced with cancer-specific DNA hypermethylation.","date":"2009","source":"Cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/19602592","citation_count":62,"is_preprint":false},{"pmid":"20723236","id":"PMC_20723236","title":"Oncogenic role of the chromobox protein CBX7 in gastric cancer.","date":"2010","source":"Journal of experimental & clinical cancer research : CR","url":"https://pubmed.ncbi.nlm.nih.gov/20723236","citation_count":56,"is_preprint":false},{"pmid":"27326334","id":"PMC_27326334","title":"Structure-Guided Discovery of Selective Antagonists for the Chromodomain of Polycomb Repressive Protein CBX7.","date":"2016","source":"ACS medicinal chemistry letters","url":"https://pubmed.ncbi.nlm.nih.gov/27326334","citation_count":56,"is_preprint":false},{"pmid":"26175930","id":"PMC_26175930","title":"Polycomb protein family member CBX7 plays a critical role in cancer progression.","date":"2015","source":"American journal of cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/26175930","citation_count":53,"is_preprint":false},{"pmid":"31422906","id":"PMC_31422906","title":"Discovery and Characterization of a Cellular Potent Positive Allosteric Modulator of the Polycomb Repressive Complex 1 Chromodomain, CBX7.","date":"2019","source":"Cell chemical biology","url":"https://pubmed.ncbi.nlm.nih.gov/31422906","citation_count":50,"is_preprint":false},{"pmid":"34035231","id":"PMC_34035231","title":"CBX7 suppresses urinary bladder cancer progression via modulating AKR1B10-ERK signaling.","date":"2021","source":"Cell death & disease","url":"https://pubmed.ncbi.nlm.nih.gov/34035231","citation_count":45,"is_preprint":false},{"pmid":"29309209","id":"PMC_29309209","title":"Robustness of In Vitro Selection Assays of DNA-Encoded Peptidomimetic Ligands to CBX7 and CBX8.","date":"2018","source":"SLAS discovery : advancing life sciences R & D","url":"https://pubmed.ncbi.nlm.nih.gov/29309209","citation_count":44,"is_preprint":false},{"pmid":"28030829","id":"PMC_28030829","title":"CBX7 suppresses cell proliferation, migration, and invasion through the inhibition of PTEN/Akt signaling in pancreatic cancer.","date":"2017","source":"Oncotarget","url":"https://pubmed.ncbi.nlm.nih.gov/28030829","citation_count":43,"is_preprint":false},{"pmid":"21060834","id":"PMC_21060834","title":"Polycomb CBX7 directly controls trimethylation of histone H3 at lysine 9 at the p16 locus.","date":"2010","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/21060834","citation_count":42,"is_preprint":false},{"pmid":"30584339","id":"PMC_30584339","title":"miRNA-19 promotes non-small-cell lung cancer cell proliferation via inhibiting CBX7 expression.","date":"2018","source":"OncoTargets and therapy","url":"https://pubmed.ncbi.nlm.nih.gov/30584339","citation_count":36,"is_preprint":false},{"pmid":"33400401","id":"PMC_33400401","title":"Multiomics integrative analysis reveals antagonistic roles of CBX2 and CBX7 in metabolic reprogramming of breast cancer.","date":"2021","source":"Molecular oncology","url":"https://pubmed.ncbi.nlm.nih.gov/33400401","citation_count":36,"is_preprint":false},{"pmid":"27449098","id":"PMC_27449098","title":"Ago-RIP-Seq identifies Polycomb repressive complex I member CBX7 as a major target of miR-375 in prostate cancer progression.","date":"2016","source":"Oncotarget","url":"https://pubmed.ncbi.nlm.nih.gov/27449098","citation_count":36,"is_preprint":false},{"pmid":"32205869","id":"PMC_32205869","title":"CBX7 binds the E-box to inhibit TWIST-1 function and inhibit tumorigenicity and metastatic potential.","date":"2020","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/32205869","citation_count":34,"is_preprint":false},{"pmid":"27291091","id":"PMC_27291091","title":"Cbx7 is epigenetically silenced in glioblastoma and inhibits cell migration by targeting YAP/TAZ-dependent transcription.","date":"2016","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/27291091","citation_count":33,"is_preprint":false},{"pmid":"28388562","id":"PMC_28388562","title":"CBX7 negatively regulates migration and invasion in glioma via Wnt/β-catenin pathway inactivation.","date":"2017","source":"Oncotarget","url":"https://pubmed.ncbi.nlm.nih.gov/28388562","citation_count":33,"is_preprint":false},{"pmid":"30759399","id":"PMC_30759399","title":"CBX7 Induces Self-Renewal of Human Normal and Malignant Hematopoietic Stem and Progenitor Cells by Canonical and Non-canonical Interactions.","date":"2019","source":"Cell reports","url":"https://pubmed.ncbi.nlm.nih.gov/30759399","citation_count":33,"is_preprint":false},{"pmid":"25596753","id":"PMC_25596753","title":"Up-regulation of miR-9 target CBX7 to regulate invasion ability of bladder transitional cell carcinoma.","date":"2015","source":"Medical science monitor : international medical journal of experimental and clinical research","url":"https://pubmed.ncbi.nlm.nih.gov/25596753","citation_count":32,"is_preprint":false},{"pmid":"22544325","id":"PMC_22544325","title":"Tumor suppressor activity of CBX7 in lung carcinogenesis.","date":"2012","source":"Cell cycle (Georgetown, Tex.)","url":"https://pubmed.ncbi.nlm.nih.gov/22544325","citation_count":30,"is_preprint":false},{"pmid":"24865347","id":"PMC_24865347","title":"CBX7 modulates the expression of genes critical for cancer progression.","date":"2014","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/24865347","citation_count":29,"is_preprint":false},{"pmid":"32201260","id":"PMC_32201260","title":"The Crosstalk between lncRNA-SNHG7/miRNA-181/cbx7 Modulates Malignant Character in Lung Adenocarcinoma.","date":"2020","source":"The American journal of pathology","url":"https://pubmed.ncbi.nlm.nih.gov/32201260","citation_count":29,"is_preprint":false},{"pmid":"31709304","id":"PMC_31709304","title":"CBX7 Inhibits Cell Growth and Motility and Induces Apoptosis in Cervical Cancer Cells.","date":"2019","source":"Molecular therapy oncolytics","url":"https://pubmed.ncbi.nlm.nih.gov/31709304","citation_count":28,"is_preprint":false},{"pmid":"24100156","id":"PMC_24100156","title":"Synthetic trimethyllysine receptors that bind histone 3, trimethyllysine 27 (H3K27me3) and disrupt its interaction with the epigenetic reader protein CBX7.","date":"2013","source":"Bioorganic & medicinal chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/24100156","citation_count":28,"is_preprint":false},{"pmid":"26216446","id":"PMC_26216446","title":"Restoration of CBX7 expression increases the susceptibility of human lung carcinoma cells to irinotecan treatment.","date":"2015","source":"Naunyn-Schmiedeberg's archives of pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/26216446","citation_count":24,"is_preprint":false},{"pmid":"35693076","id":"PMC_35693076","title":"Circ_0006790 carried by bone marrow mesenchymal stem cell-derived exosomes regulates S100A11 DNA methylation through binding to CBX7 in pancreatic ductal adenocarcinoma.","date":"2022","source":"American journal of cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/35693076","citation_count":24,"is_preprint":false},{"pmid":"28259135","id":"PMC_28259135","title":"miR-155 is positively regulated by CBX7 in mouse embryonic fibroblasts and colon carcinomas, and targets the KRAS oncogene.","date":"2017","source":"BMC cancer","url":"https://pubmed.ncbi.nlm.nih.gov/28259135","citation_count":23,"is_preprint":false},{"pmid":"35342353","id":"PMC_35342353","title":"The RNF26/CBX7 axis modulates the TNF pathway to promote cell proliferation and regulate sensitivity to TKIs in ccRCC.","date":"2022","source":"International journal of biological sciences","url":"https://pubmed.ncbi.nlm.nih.gov/35342353","citation_count":22,"is_preprint":false},{"pmid":"29073373","id":"PMC_29073373","title":"Denaturing CLIP, dCLIP, Pipeline Identifies Discrete RNA Footprints on Chromatin-Associated Proteins and Reveals that CBX7 Targets 3' UTRs to Regulate mRNA Expression.","date":"2017","source":"Cell systems","url":"https://pubmed.ncbi.nlm.nih.gov/29073373","citation_count":22,"is_preprint":false},{"pmid":"28123848","id":"PMC_28123848","title":"The malignancy of miR-18a in human glioblastoma via directly targeting CBX7.","date":"2017","source":"American journal of cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/28123848","citation_count":22,"is_preprint":false},{"pmid":"26416703","id":"PMC_26416703","title":"CBX7 and miR-9 are part of an autoregulatory loop controlling p16(INK) (4a).","date":"2015","source":"Aging cell","url":"https://pubmed.ncbi.nlm.nih.gov/26416703","citation_count":20,"is_preprint":false},{"pmid":"32390514","id":"PMC_32390514","title":"CBX7 suppression prevents ischemia-reperfusion injury-induced endoplasmic reticulum stress through the Nrf-2/HO-1 pathway.","date":"2020","source":"American journal of physiology. Renal physiology","url":"https://pubmed.ncbi.nlm.nih.gov/32390514","citation_count":20,"is_preprint":false},{"pmid":"34977026","id":"PMC_34977026","title":"PDE4B Induces Epithelial-to-Mesenchymal Transition in Bladder Cancer Cells and Is Transcriptionally Suppressed by CBX7.","date":"2021","source":"Frontiers in cell and developmental biology","url":"https://pubmed.ncbi.nlm.nih.gov/34977026","citation_count":19,"is_preprint":false},{"pmid":"29386090","id":"PMC_29386090","title":"[ARTICLE WITHDRAWN] MicroRNA-18a Targets IRF2 and CBX7 to Promote Cell Proliferation in Hepatocellular Carcinoma.","date":"2018","source":"Oncology research","url":"https://pubmed.ncbi.nlm.nih.gov/29386090","citation_count":19,"is_preprint":false},{"pmid":"37158107","id":"PMC_37158107","title":"Polycomb Group Protein CBX7 Represses Cardiomyocyte Proliferation Through Modulation of the TARDBP/RBM38 Axis.","date":"2023","source":"Circulation","url":"https://pubmed.ncbi.nlm.nih.gov/37158107","citation_count":18,"is_preprint":false},{"pmid":"34659360","id":"PMC_34659360","title":"CBX7 is Dualistic in Cancer Progression Based on its Function and Molecular Interactions.","date":"2021","source":"Frontiers in genetics","url":"https://pubmed.ncbi.nlm.nih.gov/34659360","citation_count":17,"is_preprint":false},{"pmid":"25881303","id":"PMC_25881303","title":"Critical evaluation of Cbx7 downregulation in primary colon carcinomas and its clinical significance in Chinese patients.","date":"2015","source":"BMC cancer","url":"https://pubmed.ncbi.nlm.nih.gov/25881303","citation_count":17,"is_preprint":false},{"pmid":"31211140","id":"PMC_31211140","title":"Single Nucleotide Polymorphisms of CBX4 and CBX7 Decrease the Risk of Hepatocellular Carcinoma.","date":"2019","source":"BioMed research international","url":"https://pubmed.ncbi.nlm.nih.gov/31211140","citation_count":17,"is_preprint":false},{"pmid":"29717132","id":"PMC_29717132","title":"Potential role of CBX7 in regulating pluripotency of adult human pluripotent-like olfactory stem cells in stroke model.","date":"2018","source":"Cell death & disease","url":"https://pubmed.ncbi.nlm.nih.gov/29717132","citation_count":17,"is_preprint":false},{"pmid":"29459770","id":"PMC_29459770","title":"Polycomb protein family member CBX7 regulates intrinsic axon growth and regeneration.","date":"2018","source":"Cell death and differentiation","url":"https://pubmed.ncbi.nlm.nih.gov/29459770","citation_count":16,"is_preprint":false},{"pmid":"32273717","id":"PMC_32273717","title":"lncRNA NEAT1 Facilitates Cell Proliferation, Invasion and Migration by Regulating CBX7 and RTCB in Breast Cancer.","date":"2020","source":"OncoTargets and therapy","url":"https://pubmed.ncbi.nlm.nih.gov/32273717","citation_count":15,"is_preprint":false},{"pmid":"32621571","id":"PMC_32621571","title":"Resveratrol inhibits oral squamous cell carcinoma cells proliferation while promoting apoptosis through inhibition of CBX7 protein.","date":"2020","source":"Environmental toxicology","url":"https://pubmed.ncbi.nlm.nih.gov/32621571","citation_count":15,"is_preprint":false},{"pmid":"25434821","id":"PMC_25434821","title":"Tracing dynamics and clonal heterogeneity of Cbx7-induced leukemic stem cells by cellular barcoding.","date":"2014","source":"Stem cell reports","url":"https://pubmed.ncbi.nlm.nih.gov/25434821","citation_count":15,"is_preprint":false},{"pmid":"30023485","id":"PMC_30023485","title":"Structure-Activity Relationships of Cbx7 Inhibitors, Including Selectivity Studies against Other Cbx Proteins.","date":"2016","source":"ACS omega","url":"https://pubmed.ncbi.nlm.nih.gov/30023485","citation_count":14,"is_preprint":false},{"pmid":"38037081","id":"PMC_38037081","title":"Adipose-derived exosomal miR-421 targets CBX7 and promotes metastatic potential in ovarian cancer cells.","date":"2023","source":"Journal of ovarian research","url":"https://pubmed.ncbi.nlm.nih.gov/38037081","citation_count":13,"is_preprint":false},{"pmid":"36396821","id":"PMC_36396821","title":"Downregulation of CBX7 induced by EZH2 upregulates FGFR3 expression to reduce sensitivity to cisplatin in bladder cancer.","date":"2022","source":"British journal of cancer","url":"https://pubmed.ncbi.nlm.nih.gov/36396821","citation_count":13,"is_preprint":false},{"pmid":"33245100","id":"PMC_33245100","title":"Regulation of circGOLPH3 and its binding protein CBX7 on the proliferation and apoptosis of prostate cancer cells.","date":"2020","source":"Bioscience reports","url":"https://pubmed.ncbi.nlm.nih.gov/33245100","citation_count":13,"is_preprint":false},{"pmid":"35867177","id":"PMC_35867177","title":"Liver-specific deletion of miR-181ab1 reduces liver tumour progression via upregulation of CBX7.","date":"2022","source":"Cellular and molecular life sciences : CMLS","url":"https://pubmed.ncbi.nlm.nih.gov/35867177","citation_count":13,"is_preprint":false},{"pmid":"27271093","id":"PMC_27271093","title":"CBX7 deficiency plays a positive role in dentin and alveolar bone development.","date":"2016","source":"Journal of molecular histology","url":"https://pubmed.ncbi.nlm.nih.gov/27271093","citation_count":12,"is_preprint":false},{"pmid":"24194518","id":"PMC_24194518","title":"Mitogen-activated protein kinase signaling mediates phosphorylation of polycomb ortholog Cbx7.","date":"2013","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/24194518","citation_count":11,"is_preprint":false},{"pmid":"38413558","id":"PMC_38413558","title":"IGF-1-mediated FOXC1 overexpression induces stem-like properties through upregulating CBX7 and IGF-1R in esophageal squamous cell carcinoma.","date":"2024","source":"Cell death discovery","url":"https://pubmed.ncbi.nlm.nih.gov/38413558","citation_count":11,"is_preprint":false},{"pmid":"36222130","id":"PMC_36222130","title":"Knockdown of CBX7 inhibits ferroptosis in rats with cerebral ischemia and improves cognitive dysfunction by activating the Nrf2/HO-1 pathway.","date":"2022","source":"Journal of biosciences","url":"https://pubmed.ncbi.nlm.nih.gov/36222130","citation_count":11,"is_preprint":false},{"pmid":"35843065","id":"PMC_35843065","title":"CBX7 regulates metastasis of basal-like breast cancer through Twist1/EphA2 pathway.","date":"2022","source":"Translational oncology","url":"https://pubmed.ncbi.nlm.nih.gov/35843065","citation_count":10,"is_preprint":false},{"pmid":"32495862","id":"PMC_32495862","title":"MicroRNA-18a suppresses ovarian carcinoma progression by targeting CBX7 and regulating ERK/MAPK signaling pathway and epithelial-to-mesenchymal transition.","date":"2020","source":"European review for medical and pharmacological sciences","url":"https://pubmed.ncbi.nlm.nih.gov/32495862","citation_count":10,"is_preprint":false},{"pmid":"31630421","id":"PMC_31630421","title":"Mechanisms of ischaemic neural progenitor proliferation: a regulatory role of the HIF-1α-CBX7 pathway.","date":"2019","source":"Neuropathology and applied neurobiology","url":"https://pubmed.ncbi.nlm.nih.gov/31630421","citation_count":10,"is_preprint":false},{"pmid":"18686603","id":"PMC_18686603","title":"[MiR-9 regulates the expression of CBX7 in human glioma].","date":"2008","source":"Zhongguo yi xue ke xue yuan xue bao. Acta Academiae Medicinae Sinicae","url":"https://pubmed.ncbi.nlm.nih.gov/18686603","citation_count":10,"is_preprint":false},{"pmid":"38157079","id":"PMC_38157079","title":"LncRNA RNA ROR Aggravates Hypoxia/Reoxygenation-Induced Cardiomyocyte Ferroptosis by Targeting miR-769-5p/CBX7 Axis.","date":"2023","source":"Biochemical genetics","url":"https://pubmed.ncbi.nlm.nih.gov/38157079","citation_count":9,"is_preprint":false},{"pmid":"32415167","id":"PMC_32415167","title":"Mammalian CBX7 isoforms p36 and p22 exhibit differential responses to serum, varying functions for proliferation, and distinct subcellular localization.","date":"2020","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/32415167","citation_count":9,"is_preprint":false},{"pmid":"30238429","id":"PMC_30238429","title":"Effect of CBX7 deficiency on the socket healing after tooth extractions.","date":"2018","source":"Journal of bone and mineral metabolism","url":"https://pubmed.ncbi.nlm.nih.gov/30238429","citation_count":8,"is_preprint":false},{"pmid":"34281957","id":"PMC_34281957","title":"Expression and correlation analysis of Skp2 and CBX7 in cervical cancer.","date":"2021","source":"Journal of clinical pathology","url":"https://pubmed.ncbi.nlm.nih.gov/34281957","citation_count":7,"is_preprint":false},{"pmid":"39179168","id":"PMC_39179168","title":"CBX7 promotes choroidal neovascularization by activating the HIF-1α/VEGF pathway in choroidal vascular endothelial cells.","date":"2024","source":"Experimental eye research","url":"https://pubmed.ncbi.nlm.nih.gov/39179168","citation_count":7,"is_preprint":false},{"pmid":"31254321","id":"PMC_31254321","title":"Rational Adaptation of L3MBTL1 Inhibitors to Create Small-Molecule Cbx7 Antagonists.","date":"2019","source":"ChemMedChem","url":"https://pubmed.ncbi.nlm.nih.gov/31254321","citation_count":7,"is_preprint":false},{"pmid":"37791390","id":"PMC_37791390","title":"CBX7 reprograms metabolic flux to protect against meningioma progression by modulating the USP44/c-MYC/LDHA axis.","date":"2024","source":"Journal of molecular cell biology","url":"https://pubmed.ncbi.nlm.nih.gov/37791390","citation_count":6,"is_preprint":false},{"pmid":"39456039","id":"PMC_39456039","title":"RNF2 promotes chondrosarcoma progression by regulating ubiquitination and degradation of CBX7.","date":"2024","source":"Cancer & metabolism","url":"https://pubmed.ncbi.nlm.nih.gov/39456039","citation_count":6,"is_preprint":false},{"pmid":"25759796","id":"PMC_25759796","title":"CBX7 Expression in Oncocytic Thyroid Neoplastic Lesions (Hürthle Cell Adenomas and Carcinomas).","date":"2014","source":"European thyroid journal","url":"https://pubmed.ncbi.nlm.nih.gov/25759796","citation_count":6,"is_preprint":false},{"pmid":"29723807","id":"PMC_29723807","title":"The molecular selectivity of UNC3866 inhibitor for Polycomb CBX7 protein from molecular dynamics simulation.","date":"2018","source":"Computational biology and chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/29723807","citation_count":6,"is_preprint":false},{"pmid":"28966944","id":"PMC_28966944","title":"Producing GST-Cbx7 Fusion Proteins from Escherichia coli.","date":"2017","source":"Bio-protocol","url":"https://pubmed.ncbi.nlm.nih.gov/28966944","citation_count":6,"is_preprint":false},{"pmid":"37553450","id":"PMC_37553450","title":"Subcellular expression pattern and clinical significance of CBX2 and CBX7 in breast cancer subtypes.","date":"2023","source":"Medical molecular morphology","url":"https://pubmed.ncbi.nlm.nih.gov/37553450","citation_count":5,"is_preprint":false},{"pmid":"38744845","id":"PMC_38744845","title":"CBX7 silencing promoted liver regeneration by interacting with BMI1 and activating the Nrf2/ARE signaling pathway.","date":"2024","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/38744845","citation_count":5,"is_preprint":false},{"pmid":"35526483","id":"PMC_35526483","title":"CBX7 represses the POU2F2 to inhibit the PD-L1 expression and regulate the immune response in bladder cancer.","date":"2022","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/35526483","citation_count":5,"is_preprint":false},{"pmid":"28220557","id":"PMC_28220557","title":"Aza-amino acid scanning of chromobox homolog 7 (CBX7) ligands.","date":"2017","source":"Journal of peptide science : an official publication of the European Peptide Society","url":"https://pubmed.ncbi.nlm.nih.gov/28220557","citation_count":5,"is_preprint":false},{"pmid":"38112798","id":"PMC_38112798","title":"Decoding the interaction between miR-19a and CBX7 focusing on the implications for tumor suppression in cancer therapy.","date":"2023","source":"Medical oncology (Northwood, London, England)","url":"https://pubmed.ncbi.nlm.nih.gov/38112798","citation_count":4,"is_preprint":false},{"pmid":"36920677","id":"PMC_36920677","title":"CBX7 Rejuvenates Late Passage Dental Pulp Stem Cells by Maintaining Stemness and Pro-angiogenic Ability.","date":"2023","source":"Tissue engineering and regenerative medicine","url":"https://pubmed.ncbi.nlm.nih.gov/36920677","citation_count":4,"is_preprint":false},{"pmid":"37753387","id":"PMC_37753387","title":"Cbx7 promotes the generation of induced pluripotent stem cells.","date":"2023","source":"Regenerative therapy","url":"https://pubmed.ncbi.nlm.nih.gov/37753387","citation_count":3,"is_preprint":false},{"pmid":"38809351","id":"PMC_38809351","title":"Targeting the Ferroptosis and Endoplasmic Reticulum Stress Signaling Pathways by CBX7 in Myocardial Ischemia/reperfusion Injury.","date":"2024","source":"Cell biochemistry and biophysics","url":"https://pubmed.ncbi.nlm.nih.gov/38809351","citation_count":3,"is_preprint":false},{"pmid":"38028179","id":"PMC_38028179","title":"CBX7 is involved in the progression of cervical cancer through the ITGβ3/TGFβ1/AKT pathway.","date":"2023","source":"Oncology letters","url":"https://pubmed.ncbi.nlm.nih.gov/38028179","citation_count":2,"is_preprint":false},{"pmid":"39033888","id":"PMC_39033888","title":"A novel nanoplatform-based circCSNK1G3 affects CBX7 protein and promotes glioma cell growth.","date":"2024","source":"International journal of biological macromolecules","url":"https://pubmed.ncbi.nlm.nih.gov/39033888","citation_count":2,"is_preprint":false},{"pmid":"39613290","id":"PMC_39613290","title":"CBX7 inhibitors affect H3K9 methyltransferase-regulated gene repression in leukemic cells.","date":"2024","source":"Experimental hematology","url":"https://pubmed.ncbi.nlm.nih.gov/39613290","citation_count":2,"is_preprint":false},{"pmid":"36098711","id":"PMC_36098711","title":"The expression of miR-181b, CYLD, CBX-7, BCL2, and p53 in osteosarcoma patients and correlation with clinicopathological factors.","date":"2022","source":"Chemical biology & drug design","url":"https://pubmed.ncbi.nlm.nih.gov/36098711","citation_count":2,"is_preprint":false},{"pmid":"32848416","id":"PMC_32848416","title":"lncRNA NEAT1 Facilitates Cell Proliferation, Invasion and Migration by Regulating CBX7 and RTCB in Breast Cancer [Retraction].","date":"2020","source":"OncoTargets and therapy","url":"https://pubmed.ncbi.nlm.nih.gov/32848416","citation_count":2,"is_preprint":false},{"pmid":"41250171","id":"PMC_41250171","title":"CBX7 regulates chemotherapy-induced senescence-like growth arrest in multiple myeloma via the ERK/STAT3/PIM1 axis.","date":"2025","source":"Journal of translational medicine","url":"https://pubmed.ncbi.nlm.nih.gov/41250171","citation_count":1,"is_preprint":false},{"pmid":"41117088","id":"PMC_41117088","title":"Engineered Multifunctional Hydrogel Delivering Novel CBX7 Inhibitor Modulates Cuproptosis Via Liquid-Liquid Phase Separation to Restore Cardiac Function in Aged Myocardial Infarction.","date":"2025","source":"Advanced science (Weinheim, Baden-Wurttemberg, Germany)","url":"https://pubmed.ncbi.nlm.nih.gov/41117088","citation_count":1,"is_preprint":false},{"pmid":"40998236","id":"PMC_40998236","title":"Chromobox protein homolog 7 (CBX7) deficiency inhibits osteoblast ferroptosis by activating the Nrf2 function in type 2 diabetic osteoporosis.","date":"2025","source":"The international journal of biochemistry & cell biology","url":"https://pubmed.ncbi.nlm.nih.gov/40998236","citation_count":1,"is_preprint":false},{"pmid":"40387566","id":"PMC_40387566","title":"DNMT1-Induced Downregulation of CBX7 Inhibits ERK Phosphorylation and Promotes Pancreatic Ductal Adenocarcinoma Progression.","date":"2025","source":"FASEB journal : official publication of the Federation of American Societies for Experimental Biology","url":"https://pubmed.ncbi.nlm.nih.gov/40387566","citation_count":0,"is_preprint":false},{"pmid":"37986971","id":"PMC_37986971","title":"Adipose-derived exosomal miR-421 targets CBX7 and promotes metastatic potential in ovarian cancer cells.","date":"2023","source":"bioRxiv : the preprint server for biology","url":"https://pubmed.ncbi.nlm.nih.gov/37986971","citation_count":0,"is_preprint":false},{"pmid":"40552137","id":"PMC_40552137","title":"Pharmacological targeting of CBX7 alters the epigenetic landscape and induces differentiation of leukemic cells.","date":"2024","source":"Blood neoplasia","url":"https://pubmed.ncbi.nlm.nih.gov/40552137","citation_count":0,"is_preprint":false},{"pmid":"41686891","id":"PMC_41686891","title":"CBX7 functions as a methylation-dependent inducer of gene transcription and regulator of cytosolic signaling in lymphoid cells.","date":"2026","source":"Science advances","url":"https://pubmed.ncbi.nlm.nih.gov/41686891","citation_count":0,"is_preprint":false},{"pmid":"41582043","id":"PMC_41582043","title":"Histone H3.3 phosphorylation facilitates H3K9me3-heterochromatin formation during retrotransposon silencing and X-chromosome inactivation via H3.3K27me3-CBX7-KAP1 axis.","date":"2026","source":"Science bulletin","url":"https://pubmed.ncbi.nlm.nih.gov/41582043","citation_count":0,"is_preprint":false},{"pmid":"39322790","id":"PMC_39322790","title":"Study on the Role of EPHB6 in Inhibiting the Malignant Progression of Cervical Cancer C33A Cells by Binding to CBX7.","date":"2024","source":"Cell biochemistry and biophysics","url":"https://pubmed.ncbi.nlm.nih.gov/39322790","citation_count":0,"is_preprint":false}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":49515,"output_tokens":9180,"usd":0.143123,"stage1_stop_reason":"end_turn"},"stage2":{"model":"claude-opus-4-8","input_tokens":19198,"output_tokens":9625,"usd":0.168307,"stage2_stop_reason":"end_turn"},"total_usd":0.31143,"stage1_batch_id":"msgbatch_01ACAxJQabDsht39JXeWG22d","stage2_batch_id":"msgbatch_01QEU22A9U5sbPTgsMzTmvSf","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 2003,\n      \"finding\": \"CBX7 interacts with Ring1 and localizes to nuclear Polycomb bodies, functioning as a PRC1 component to repress the Ink4a/Arf locus and extend cellular lifespan; shRNA ablation of CBX7 induced growth arrest via induction of Ink4a/Arf.\",\n      \"method\": \"Co-immunoprecipitation (Ring1 interaction), immunofluorescence (nuclear Polycomb body localization), shRNA knockdown with p16/Arf induction readout, cDNA screen for senescence bypass\",\n      \"journal\": \"Nature cell biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — reciprocal functional validation (overexpression + shRNA KD), localization confirmed, replicated mechanistic readout across multiple cell types\",\n      \"pmids\": [\"14647293\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"CBX7 within PRC1 binds directly to the noncoding RNA ANRIL via its chromodomain; in concert with H3K27me3 recognition, RNA binding is required for CBX7-mediated repression of the INK4b/ARF/INK4a locus. Structure-guided analysis revealed the molecular interplay between noncoding RNA and H3K27me3 as mediated by the conserved chromodomain.\",\n      \"method\": \"RNA immunoprecipitation, NMR structural analysis of chromodomain–RNA interaction, chromodomain mutants disrupting RNA or H3K27me binding, ChIP at INK4a/ARF locus, senescence assays\",\n      \"journal\": \"Molecular cell\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — structural analysis combined with mutagenesis and functional validation, multiple orthogonal methods in one study\",\n      \"pmids\": [\"20541999\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2005,\n      \"finding\": \"CBX7 represses p16INK4a and p14ARF expression in normal and tumor-derived prostate cells; shRNA knockdown upregulates both p16 and p14ARF and impairs cell growth in a manner dependent on the p16/Rb and p14ARF/p53 pathway status.\",\n      \"method\": \"shRNA knockdown, Western blot for p16/p14ARF, growth assays in LNCaP and PC-3 cells\",\n      \"journal\": \"Oncogene\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — clean KD with defined pathway-level readout, single lab, two cell line models\",\n      \"pmids\": [\"15897876\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2007,\n      \"finding\": \"CBX7 represses the Ink4a/Arf locus and acts epistatically to the Arf-p53 pathway during lymphomagenesis in vivo; transgenic targeting of Cbx7 to the lymphoid compartment initiated T cell lymphomagenesis and cooperated with c-Myc to produce B cell lymphomas.\",\n      \"method\": \"Transgenic mouse model (lymphoid-targeted Cbx7 expression), genetic epistasis with Arf-p53 pathway, tumor characterization\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — in vivo epistasis in transgenic mouse model with defined pathway placement, replicated across lymphoma types\",\n      \"pmids\": [\"17374722\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2009,\n      \"finding\": \"CBX7 (PRC1 component) physically associates with DNA methyltransferase (DNMT) enzymes; CBX7 can initiate stable repression and promoter DNA hypermethylation of cancer-silenced genes in embryonal carcinoma cells, and DNMTs are assembled at CBX7 target gene promoters.\",\n      \"method\": \"Co-immunoprecipitation (CBX7–DNMT interaction), ChIP (DNMT assembly at CBX7 target promoters), CBX7 knockdown/sustained expression in EC cells, epigenomic analysis\",\n      \"journal\": \"Cancer research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — Co-IP plus ChIP plus functional gain/loss experiments, single lab\",\n      \"pmids\": [\"19602592\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"CBX7 recruits the H3K9 methyltransferase SUV39H2 to the p16 promoter, initiating H3K9me3 formation; chromodomain mutations or Pc-box deletion abolished CBX7 binding and H3K9me3 formation; CBX7–SUV39H2 complexes were detected in the nucleus by bimolecular fluorescence complementation.\",\n      \"method\": \"ChIP (CBX7, SUV39H2, H3K9me3 at p16 locus), BiFC (CBX7–SUV39H2 nuclear complex), chromodomain/Pc-box mutants, siRNA knockdown of Suv39h2\",\n      \"journal\": \"PloS one\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — multiple orthogonal methods (ChIP, BiFC, mutagenesis, siRNA) in single lab\",\n      \"pmids\": [\"21060834\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"CBX7 is necessary for recruitment of Ring1B to chromatin in ESCs; Cbx7-containing PRC1 complexes primarily control early-lineage commitment whereas RYBP-containing PRC1 complexes regulate metabolism and cell-cycle progression. Cbx7 is the primary Polycomb ortholog of PRC1 in ESCs and directly represses Cbx2, Cbx4, and Cbx8.\",\n      \"method\": \"ChIP-seq (genomic localization), Cbx7 knockdown (Ring1B chromatin recruitment), reporter assays, ESC differentiation assays\",\n      \"journal\": \"Cell reports\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — genome-wide ChIP-seq plus functional KD with defined mechanistic readout, replicated across two papers (PMID:23273917, PMID:22226354)\",\n      \"pmids\": [\"23273917\", \"22226354\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"Cbx7 knockout mice develop liver and lung adenomas and carcinomas; Cbx7 null MEFs show increased proliferation and reduced senescence; CBX7 binds the CCNE1 (cyclin E) promoter in a complex containing HDAC2 and negatively regulates CCNE1 expression.\",\n      \"method\": \"Cbx7 knockout mouse generation, ChIP (CBX7 and HDAC2 at CCNE1 promoter), Western blot, MEF proliferation/senescence assays, human tumor tissue correlation\",\n      \"journal\": \"The Journal of clinical investigation\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 / Strong — in vivo KO phenotype combined with ChIP demonstrating direct promoter occupancy and co-repressor complex, orthogonal validation in human tumors\",\n      \"pmids\": [\"22214847\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"MAPK signaling phosphorylates Cbx7 at Thr-118 (near the Polycomb box); a site-specific antibody confirms this phosphorylation in mammary carcinoma cells blocked by MEK inhibitors; upon EGF stimulation, phosphorylated Cbx7 interacts more robustly with other PRC1 members; Thr-118 phosphorylation moderately enhances repression of the p16 target gene in RAS-induced senescence.\",\n      \"method\": \"Mass spectrometry identification of phosphorylation site, site-specific antibody generation, MEK inhibitor treatment, EGF stimulation + Co-IP with PRC1 members, p16 repression assay with phosphomimetic mutant\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 1–2 / Moderate — biochemical and MS identification of PTM site plus functional mutagenesis in senescence model, single lab\",\n      \"pmids\": [\"24194518\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"CBX7 inhibits Wnt/β-catenin signaling in breast epithelial cells by enhancing transcription of DKK-1 (a Wnt antagonist) through cooperation with p300 acetyltransferase and increased histone acetylation at the DKK-1 promoter; DKK-1 pharmacological inhibition in CBX7-overexpressing cells rescues Wnt signaling and the CD44+/CD24-/ESA+ stem-like cell population.\",\n      \"method\": \"ChIP (CBX7 and p300 at DKK-1 promoter, histone acetylation), shRNA knockdown and overexpression, pharmacological DKK-1 inhibition, stem-cell population assays\",\n      \"journal\": \"FASEB journal\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — ChIP evidence for direct promoter occupancy and co-activator interaction, functional rescue experiment, single lab\",\n      \"pmids\": [\"25351982\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"CBX7 negatively or positively regulates several cancer-relevant genes (e.g., SPP1/osteopontin repressed; FOS/FOSB/EGR1 activated) by interacting with their promoter regions and modulating transcriptional activity, as shown by ChIP and gene expression profiling after CBX7 restoration.\",\n      \"method\": \"Gene expression profiling after CBX7 restoration, ChIP at gene promoters, qRT-PCR correlation in human thyroid and lung carcinoma tissues\",\n      \"journal\": \"PloS one\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — ChIP plus expression profiling plus tissue correlation, single lab\",\n      \"pmids\": [\"24865347\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"Crystal structures of CBX7 chromodomain with small-molecule inhibitors reveal the binding modes; inhibitors compete with H3K27me3 peptide binding through interactions with key residues in the methyl-lysine binding aromatic cage; lead compound MS37452 displaces CBX7 from the INK4A/ARF locus and derepresses p16/CDKN2A transcription in prostate cancer cells.\",\n      \"method\": \"X-ray crystallography of CBX7ChD–inhibitor complexes, fluorescence polarization binding assays, ChIP (CBX7 displacement from INK4A/ARF locus), gene expression assays in PC3 cells\",\n      \"journal\": \"Chemistry & biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — crystal structures plus cellular functional validation, multiple orthogonal methods, single lab\",\n      \"pmids\": [\"25660273\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"By live-cell single-molecule tracking, Cbx7 requires co-recognition of both H3K27me3 and DNA for chromatin targeting; the chromodomain (CD) and AT-hook-like (ATL) motif constitute a functional DNA-binding unit; H3K27me3 contributes significantly to Cbx7 and Cbx8 chromatin targeting but less to Cbx2, Cbx4, Cbx6; disruption of PRC1 complex formation facilitates Cbx7 chromatin targeting.\",\n      \"method\": \"Live-cell single-molecule tracking (SMT), CRISPR genetic engineering of H3K27me3 pathway, biochemical DNA-binding assays, Cbx7 CD and ATL mutants\",\n      \"journal\": \"eLife\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 / Strong — single-molecule live-cell imaging combined with genetic disruption and biochemical assays, multiple orthogonal methods\",\n      \"pmids\": [\"27723458\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"Structure-guided discovery of Class B antagonist MS351, which inhibits H3K27me3 binding when CBX7ChD is bound to RNA; crystal structure of CBX7ChD/MS351 reveals ligand recognition by aromatic cage residues; MS351 induces derepression of CBX7 target genes including p16 in mESCs and PC3 cells.\",\n      \"method\": \"X-ray crystallography of CBX7ChD/MS351 complex, fluorescence polarization assays, gene expression assays (p16 derepression in mESC and PC3)\",\n      \"journal\": \"ACS medicinal chemistry letters\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — crystal structure plus functional cellular validation, multiple orthogonal methods, single lab\",\n      \"pmids\": [\"27326334\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"dCLIP reveals that CBX7 predominantly binds 3' UTRs of mRNAs with a median footprint of ~171–183 nucleotides; four families of consensus RNA motifs were identified and their mutation abolishes CBX7 binding in vitro; antisense oligonucleotide intervention paradoxically increases CBX7 binding and enhances gene expression.\",\n      \"method\": \"Denaturing CLIP (dCLIP) in mouse and human cells, bioinformatic motif analysis, in vitro RNA binding with motif-mutant constructs, antisense oligonucleotide pharmacological intervention\",\n      \"journal\": \"Cell systems\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 / Strong — dCLIP in two species with motif mutagenesis and in vitro validation, multiple orthogonal methods\",\n      \"pmids\": [\"29073373\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"CBX7 positively regulates miR-155 expression in MEFs and colon carcinomas, and miR-155 in turn targets KRAS protein levels; Cbx7-null MEFs show downregulation of miR-155 and corresponding upregulation of KRAS protein.\",\n      \"method\": \"miRNA microarray of Cbx7-null vs. WT MEFs, qRT-PCR validation, miR-155 transfection with Western blot for KRAS, human colon carcinoma tissue correlation\",\n      \"journal\": \"BMC cancer\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — KO model plus miRNA array plus functional transfection and target validation, single lab\",\n      \"pmids\": [\"28259135\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"CBX7 represses YAP/TAZ-dependent transcription in glioblastoma; CBX7 overexpression represses CTGF (a YAP/TAZ target) and reduces phospho-JNK; CBX7 fails to inhibit glioma cell migration when CTGF is exogenously overexpressed or constitutively active JNK is present, placing CBX7 upstream of the YAP/TAZ-CTGF-JNK axis.\",\n      \"method\": \"Exogenous CBX7 overexpression, GSEA of CBX7-regulated genes identifying YAP/TAZ targets, Western blot (CTGF, p-JNK), genetic rescue experiments (CTGF OE, CA-JNK), migration assays\",\n      \"journal\": \"Scientific reports\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — epistasis by genetic rescue, GSEA pathway placement, single lab\",\n      \"pmids\": [\"27291091\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"CBX7 interacts with non-histone proteins bearing trimethylated lysine peptide motifs similar to H3K27me3: the H3K9 methyltransferases SETDB1, EHMT1, and EHMT2 were identified as CBX7-binding proteins by mass spectrometry; depletion of SETDB1 in AML cells phenocopied CBX7 repression.\",\n      \"method\": \"Mass spectrometry of CBX7-associated proteins, Co-IP validation, SETDB1 knockdown phenocopy assay in AML cells, xenotransplantation of CBX7-overexpressing HSPCs\",\n      \"journal\": \"Cell reports\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — MS-based interactome with functional phenocopy validation, single lab\",\n      \"pmids\": [\"30759399\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"A positive allosteric modulator (PAM) peptidomimetic UNC4976 simultaneously antagonizes H3K27me3-specific recruitment of CBX7 to target genes while increasing non-specific DNA/RNA binding, re-equilibrating PRC1 away from H3K27me3 target regions; this was demonstrated across three orthogonal cellular assays.\",\n      \"method\": \"Quantitative cellular CBX7 chromodomain assay, ChIP (target gene displacement), fluorescence polarization, cellular reporter assays\",\n      \"journal\": \"Cell chemical biology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — three orthogonal cellular assays plus mechanistic ChIP, single lab\",\n      \"pmids\": [\"31422906\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"CBX7 binds directly to the E-box element to preclude TWIST-1 from binding its E-box in secondary ovarian cancer cells; deletion of CBX7 reactivates TWIST-1-induced transcription and promotes mesenchymal transformation and enhanced tumorigenicity in vivo.\",\n      \"method\": \"CBX7 deletion (CRISPR/genetic), reporter assays for TWIST-1 transcriptional activity at E-box, in vivo tumorigenicity assays\",\n      \"journal\": \"Oncogene\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — genetic deletion with direct transcriptional readout and in vivo validation, single lab\",\n      \"pmids\": [\"32205869\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"The two CBX7 isoforms p36CBX7 and p22CBX7 exhibit distinct subcellular localization and opposing proliferative functions: p36CBX7 localizes to the nucleus and is expressed in proliferating cells, while p22CBX7 localizes to the cytoplasm, is induced by serum starvation, and inhibits cell proliferation.\",\n      \"method\": \"Isoform identification by molecular cloning, subcellular fractionation, immunofluorescence, serum starvation experiments, proliferation assays\",\n      \"journal\": \"Scientific reports\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — direct localization by fractionation/immunofluorescence with functional proliferation consequence, single lab\",\n      \"pmids\": [\"32415167\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"CBX7 transcriptionally suppresses AKR1B10 in a PRC1-dependent manner (identified by RNA-seq and ChIP); AKR1B10 downregulation by CBX7 inactivates ERK signaling, establishing a CBX7/AKR1B10/ERK signaling axis in urinary bladder cancer.\",\n      \"method\": \"RNA-seq after CBX7 manipulation, ChIP assay at AKR1B10 locus, siRNA knockdown of AKR1B10, ERK signaling Western blot, xenograft tumor models\",\n      \"journal\": \"Cell death & disease\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — RNA-seq plus ChIP plus genetic rescue in a defined signaling axis, single lab\",\n      \"pmids\": [\"34035231\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"CBX7 transcriptionally suppresses PDE4B at the transcription level in a PRC1-dependent manner in bladder cancer cells, as demonstrated by ChIP and luciferase assays.\",\n      \"method\": \"ChIP (CBX7 at PDE4B promoter), luciferase reporter assay, CBX7 knockdown/overexpression with PDE4B expression readout\",\n      \"journal\": \"Frontiers in cell and developmental biology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — ChIP plus reporter assay demonstrating direct transcriptional repression, single lab\",\n      \"pmids\": [\"34977026\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"RNF26 promotes ubiquitin-mediated proteasomal degradation of CBX7 in clear cell renal cell carcinoma; RNF26 knockdown reduces CBX7 ubiquitination, stabilizes CBX7 protein, and inhibits tumor growth, establishing RNF26 as a CBX7 E3 ubiquitin ligase.\",\n      \"method\": \"Co-IP (RNF26–CBX7 interaction), ubiquitination assay, cycloheximide chase (protein stability), RNF26 KD/OE with CBX7 protein level readout, xenograft models\",\n      \"journal\": \"International journal of biological sciences\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — ubiquitination assay plus stability chase plus Co-IP, single lab\",\n      \"pmids\": [\"35342353\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"EZH2 represses CBX7 expression by increasing H3K27me3 at the CBX7 promoter in bladder cancer cells; CBX7 in turn directly downregulates FGFR3 expression (shown by ChIP-qPCR) and sensitizes bladder cancer cells to cisplatin by inactivating PI3K-AKT signaling.\",\n      \"method\": \"ChIP-qPCR (H3K27me3 at CBX7 promoter; CBX7 at FGFR3 promoter), RT-qPCR, Western blot, CCK-8 cisplatin sensitivity assay, xenograft mouse model\",\n      \"journal\": \"British journal of cancer\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — ChIP-qPCR showing direct promoter occupancy at two levels of the axis, xenograft validation, single lab\",\n      \"pmids\": [\"36396821\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"CBX7 downregulates POU2F2 expression, which indirectly represses PD-L1 in bladder cancer cells; depletion of CBX7 results in resistance to PD-1 blockade, establishing a CBX7/POU2F2/PD-L1 regulatory axis.\",\n      \"method\": \"RNA-seq (CBX7 KD, GSE185630), Western blot/RT-qPCR (POU2F2, PD-L1), PD-1 blockade functional assay\",\n      \"journal\": \"Biochemical and biophysical research communications\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 3 / Weak — pathway inferred from RNA-seq plus Western blot, indirect (POU2F2 intermediate not directly shown bound to PD-L1 promoter by CBX7), single lab\",\n      \"pmids\": [\"35526483\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"Circ_0006790 facilitates nuclear translocation of CBX7; nuclear CBX7 increases DNA methylation of S100A11 by recruiting DNA methyltransferases to its promoter, thereby inhibiting S100A11 transcription and suppressing PDAC immune escape.\",\n      \"method\": \"RNA pull-down and RIP (circ_6790–CBX7 interaction), subcellular fractionation (CBX7 nuclear translocation), ChIP (DNMT recruitment to S100A11 promoter), siRNA knockdowns, xenograft assays\",\n      \"journal\": \"American journal of cancer research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — pull-down, fractionation, ChIP, and functional rescue in a single study, single lab\",\n      \"pmids\": [\"35693076\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"CBX7 interacts with TARDBP (TDP-43) and positively regulates its downstream target RBM38 in a TARDBP-dependent manner; this CBX7–TARDBP–RBM38 axis drives cardiomyocyte cell cycle exit postnatally, and Cbx7 genetic inactivation promotes cardiomyocyte proliferation and cardiac regeneration after injury.\",\n      \"method\": \"Co-immunoprecipitation + mass spectrometry (CBX7–TARDBP interaction), conditional and inducible cardiac-specific KO mice, adenoviral CBX7 overexpression, immunostaining for proliferation markers, neonatal apical resection and adult MI models\",\n      \"journal\": \"Circulation\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — MS-identified interaction confirmed by Co-IP, genetic KO with specific proliferative phenotype, in vivo cardiac regeneration models, multiple orthogonal methods\",\n      \"pmids\": [\"37158107\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"CBX7 transcriptionally inhibits USP44 expression; reduced USP44 promotes proteasome-dependent degradation of c-MYC protein, consequently attenuating c-MYC-mediated transactivation of LDHA and inhibiting glycolysis in meningioma cells.\",\n      \"method\": \"iTRAQ proteomics after CBX7 restoration, ChIP (CBX7 at USP44 promoter), luciferase reporter assay, Western blot (c-MYC stability), proteasome inhibitor experiments, xenograft mouse models\",\n      \"journal\": \"Journal of molecular cell biology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — ChIP plus reporter assay plus proteasome inhibitor rescue, iTRAQ proteomics, single lab\",\n      \"pmids\": [\"37791390\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"CBX7 blocks Twist1 binding to the EphA2 promoter and inhibits EphA2 expression; loss of CBX7 allows Twist1 to transactivate EphA2, promoting BLBC metastasis via the Twist1/EphA2 axis.\",\n      \"method\": \"ChIP assay (Twist1 at EphA2 promoter with/without CBX7), dual-luciferase reporter assay, Western blot, in vitro migration/invasion assays\",\n      \"journal\": \"Translational oncology\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 3 / Weak — single lab, ChIP and reporter without direct CBX7–Twist1 binding characterization\",\n      \"pmids\": [\"35843065\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"RNF2 promotes ubiquitination and proteasomal degradation of CBX7 in chondrosarcoma; RNF2 knockdown reduces CBX7 ubiquitination and increases CBX7 protein stability (cycloheximide chase), without affecting CBX7 mRNA levels.\",\n      \"method\": \"Co-IP, ubiquitination assay, cycloheximide chase (protein stability), RNF2 KD/OE with CBX7 readout, xenograft mouse model\",\n      \"journal\": \"Cancer & metabolism\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — ubiquitination assay plus stability chase plus Co-IP in multiple cell systems, single lab\",\n      \"pmids\": [\"39456039\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"CBX7 promotes HIF-1α transcription and nuclear translocation and transcriptional activity in choroidal vascular endothelial cells under hypoxia, which in turn stimulates VEGF transcription and promotes pro-angiogenic behaviors (migration, proliferation, tube formation) via the CBX7/HIF-1α/VEGF pathway.\",\n      \"method\": \"CBX7 knockdown/overexpression in HCVECs, Western blot (HIF-1α, VEGF), nuclear fractionation (HIF-1α translocation), functional angiogenesis assays (migration, tube formation), laser-induced CNV mouse model\",\n      \"journal\": \"Experimental eye research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — multiple functional assays plus in vivo CNV model, single lab\",\n      \"pmids\": [\"39179168\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"CBX7 interacts with H3K9 methyltransferases EHMT1/2 and SETDB1; pharmacological inhibition of CBX7 abolishes this interaction, reduces H3K9 methylation, and reactivates target gene expression; CBX7 inhibitors also affect H2Aub-mediated (Polycomb) gene repression.\",\n      \"method\": \"Co-IP (CBX7–EHMT1/2/SETDB1), pharmacological CBX7 inhibitor treatment, H3K9me and H2Aub Western blot, gene expression assays, combination drug growth assays\",\n      \"journal\": \"Experimental hematology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — Co-IP plus pharmacological perturbation plus histone modification readout, single lab\",\n      \"pmids\": [\"39613290\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"DNMT1 methylates the CBX7 promoter region to repress CBX7 expression in PDAC; reduced CBX7 leads to increased ERK phosphorylation, promoting tumorigenesis and metastasis; the DNMT1/CBX7/ERK axis was confirmed by ChIP and dual-luciferase assays.\",\n      \"method\": \"ChIP (DNMT1 at CBX7 promoter), dual-luciferase reporter assay, DNMT1 knockdown with CBX7 and ERK readout, CCK-8/wound healing/transwell functional assays\",\n      \"journal\": \"FASEB journal\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — ChIP plus reporter assay plus functional rescue, single lab\",\n      \"pmids\": [\"40387566\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2026,\n      \"finding\": \"CBX7 forms a methylation-dependent transcriptional activation complex at cytokine gene promoters in lymphoid cells (unexpected activating role); CBX7 also translocates to the cytosol and forms a methylation-dependent signaling complex with c-Raf, MEK1/2, and CK2-α to sustain ERK1/2 signaling; these activities are lymphoid-cell specific and absent in epithelial cells.\",\n      \"method\": \"Co-IP (CBX7–c-Raf–MEK1/2–CK2α), ChIP (CBX7 at cytokine gene promoters), subcellular fractionation, genetic KO and pharmacological inhibition in mouse and human lymphoid cells, RNA-seq, allergic asthma mouse models\",\n      \"journal\": \"Science advances\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — Co-IP plus ChIP plus genetic/pharmacological intervention across multiple mouse models, single lab but multiple orthogonal methods\",\n      \"pmids\": [\"41686891\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2026,\n      \"finding\": \"CBX7 preferentially binds Ser31-phosphorylated H3.3K27me3 nucleosomes and recruits KAP1 (KRAB-associated protein 1); disruption of the H3.3–CBX7 interaction impairs H3K9me3 heterochromatin formation and activates retrotransposons; during X-chromosome inactivation, H3K9me2/3 fails to accumulate at the inactive X when the H3.3–CBX7–KAP1 axis is blocked.\",\n      \"method\": \"Co-IP/nucleosome pulldown (CBX7 binding to H3.3S31ph-K27me3), H3K9me3 ChIP after H3.3–CBX7 disruption, retrotransposon activation assays, X-chromosome inactivation assays\",\n      \"journal\": \"Science bulletin\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — nucleosome binding with defined modifications plus ChIP showing downstream H3K9me3 effects, single lab, functional validation in two biological contexts\",\n      \"pmids\": [\"41582043\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"CBX7 is a PRC1 chromodomain protein that recognizes H3K27me3 (and H3.3S31ph-K27me3) via its aromatic cage, co-recognizes DNA through an AT-hook-like motif, and binds noncoding RNAs including ANRIL and 3' UTRs of mRNAs to direct transcriptional repression of targets such as the INK4a/ARF locus, CCNE1, AKR1B10, FGFR3, and PDE4B; it recruits co-repressors including Ring1B, HDAC2, and H3K9 methyltransferases (SUV39H2, EHMT1/2, SETDB1), is itself phosphorylated at Thr-118 by MAPK signaling to modulate PRC1 interactions, and is subject to proteasomal degradation mediated by E3 ubiquitin ligases RNF26 and RNF2; in addition, CBX7 can function as a transcriptional activator and cytosolic signaling scaffold (with c-Raf, MEK1/2, CK2-α for ERK1/2 activation) specifically in lymphoid cells, and distinct isoforms localize differentially to nucleus versus cytoplasm with opposing effects on cell proliferation.\"\n}\n```","stage2_raw":"{\n  \"mechanistic_narrative\": \"CBX7 is a chromodomain subunit of Polycomb repressive complex 1 (PRC1) that reads repressive chromatin marks and directs transcriptional silencing of cell-cycle and tumor-suppressor loci, most prominently the INK4a/ARF locus, to control cellular senescence and proliferative lifespan [#0, #2, #7]. Chromatin targeting requires bivalent recognition: the chromodomain engages H3K27me3 — and preferentially Ser31-phosphorylated H3.3K27me3 nucleosomes — while a chromodomain–AT-hook-like (ATL) unit co-recognizes DNA, with both inputs needed for stable target binding in living cells [#12, #35]. The same chromodomain binds noncoding RNA, including ANRIL, and this RNA interaction acts in concert with H3K27me3 reading to enforce repression of INK4b/ARF/INK4a, while transcriptome-wide CLIP shows CBX7 footprints concentrated in mRNA 3' UTRs through defined sequence motifs [#1, #14]. Once recruited, CBX7 is required for Ring1B deposition on chromatin in embryonic stem cells, where it is the dominant PRC1 ortholog directing early-lineage commitment and repressing other Cbx paralogs [#6]. CBX7 nucleates layered silencing by recruiting co-repressors: HDAC2 at the CCNE1 promoter [#7], DNA methyltransferases at target promoters [#4, #26], and H3K9 methyltransferases SUV39H2, EHMT1/2 and SETDB1 to seed H3K9 methylation, the latter recognized through trimethyl-lysine motifs resembling H3K27me3 [#5, #17, #32]. Through these activities CBX7 represses a broad set of oncogenic effectors — CCNE1, AKR1B10, PDE4B, FGFR3, USP44, SPP1 and the Twist1-dependent EphA2 program — thereby restraining ERK, PI3K-AKT, c-MYC/glycolysis and metastatic transcriptional outputs [#7, #21, #22, #24, #28, #19], while in some contexts acting as a transcriptional activator, cooperating with p300 to induce the Wnt antagonist DKK-1 and activating FOS/FOSB/EGR1 [#9, #10]. CBX7 activity is itself controlled post-translationally: MAPK signaling phosphorylates Thr-118 near the Polycomb box to strengthen PRC1 association, and the E3 ligases RNF26 and RNF2 drive its ubiquitin-mediated proteasomal degradation [#8, #23, #30]. Distinct isoforms partition between nucleus and cytoplasm with opposing effects on proliferation, and beyond its canonical repressive role CBX7 functions in lymphoid cells as a cytosolic signaling scaffold for c-Raf/MEK1/2/CK2-α to sustain ERK1/2 activity and as a methylation-dependent transcriptional activator of cytokine genes [#20, #34]. CBX7 also drives a developmental cell-cycle exit program through a TARDBP/RBM38 axis that limits cardiomyocyte proliferation [#27]. The chromodomain methyl-lysine cage is a validated small-molecule target whose inhibition or allosteric re-equilibration displaces CBX7 from target loci and derepresses p16/CDKN2A [#11, #13, #18].\"\n,\n  \"teleology\": [\n    {\n      \"year\": 2003,\n      \"claim\": \"Established CBX7 as a functional PRC1 component whose repression of the Ink4a/Arf locus sets cellular proliferative lifespan, defining its core biology.\",\n      \"evidence\": \"Co-IP with Ring1, Polycomb-body immunofluorescence, and shRNA knockdown with p16/Arf readout in a senescence-bypass cDNA screen\",\n      \"pmids\": [\"14647293\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Did not resolve how CBX7 selects the INK4a/ARF locus\", \"Co-repressor machinery downstream of Ring1 not yet defined\"]\n    },\n    {\n      \"year\": 2005,\n      \"claim\": \"Extended INK4a/ARF repression to human prostate cells and showed the growth phenotype depends on intact p16/Rb and p14ARF/p53 pathways.\",\n      \"evidence\": \"shRNA knockdown with Western blot and growth assays in LNCaP and PC-3 cells\",\n      \"pmids\": [\"15897876\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Direct promoter occupancy not shown in this study\", \"Limited to two cell lines from one lab\"]\n    },\n    {\n      \"year\": 2007,\n      \"claim\": \"Placed CBX7 genetically upstream of the Arf-p53 axis in vivo, demonstrating oncogenic cooperation with c-Myc during lymphomagenesis.\",\n      \"evidence\": \"Lymphoid-targeted Cbx7 transgenic mice with genetic epistasis and tumor characterization\",\n      \"pmids\": [\"17374722\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Molecular basis of c-Myc cooperation not defined\", \"Targets beyond Ink4a/Arf in lymphoma not identified\"]\n    },\n    {\n      \"year\": 2009,\n      \"claim\": \"Connected CBX7 to DNA methylation by showing it associates with DNMTs and can seed promoter hypermethylation, linking Polycomb repression to a heritable silencing layer.\",\n      \"evidence\": \"Co-IP and ChIP for DNMT assembly at CBX7 targets with gain/loss in embryonal carcinoma cells\",\n      \"pmids\": [\"19602592\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Direct vs. indirect DNMT recruitment unresolved\", \"Single lab, single cell context\"]\n    },\n    {\n      \"year\": 2010,\n      \"claim\": \"Defined the chromodomain as a dual H3K27me3- and RNA-reader, showing ANRIL binding is required for INK4 locus repression and revealing the structural interplay between the two ligands.\",\n      \"evidence\": \"RNA-IP, NMR of chromodomain–RNA interaction, separation-of-function chromodomain mutants, ChIP and senescence assays\",\n      \"pmids\": [\"20541999\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"How RNA and H3K27me3 binding are coordinated kinetically not resolved\", \"Generality beyond ANRIL not addressed here\"]\n    },\n    {\n      \"year\": 2010,\n      \"claim\": \"Demonstrated CBX7 recruits the H3K9 methyltransferase SUV39H2 to seed H3K9me3, coupling Polycomb to H3K9 methylation in cis.\",\n      \"evidence\": \"ChIP for CBX7/SUV39H2/H3K9me3 at p16, BiFC, and chromodomain/Pc-box mutants with siRNA\",\n      \"pmids\": [\"21060834\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Direct SUV39H2 contact surface not mapped\", \"Restricted to the p16 locus\"]\n    },\n    {\n      \"year\": 2012,\n      \"claim\": \"Showed CBX7 is required for Ring1B chromatin recruitment in ESCs and is the dominant PRC1 ortholog controlling early lineage commitment and Cbx paralog repression.\",\n      \"evidence\": \"ChIP-seq, Cbx7 knockdown with Ring1B recruitment readout, reporter and differentiation assays (two papers)\",\n      \"pmids\": [\"23273917\", \"22226354\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Mechanism distinguishing Cbx7- vs RYBP-PRC1 targeting not fully defined\", \"Stoichiometry within PRC1 not measured\"]\n    },\n    {\n      \"year\": 2012,\n      \"claim\": \"An in vivo knockout established CBX7 as a tumor suppressor and identified CCNE1 as a direct target repressed via an HDAC2-containing complex.\",\n      \"evidence\": \"Cbx7 KO mice with tumor phenotype, MEF senescence assays, ChIP for CBX7/HDAC2 at CCNE1, human tumor correlation\",\n      \"pmids\": [\"22214847\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"HDAC2 recruitment mechanism not defined\", \"Full target set behind the KO phenotype unknown\"]\n    },\n    {\n      \"year\": 2013,\n      \"claim\": \"Identified Thr-118 phosphorylation by MAPK signaling as a switch that strengthens CBX7–PRC1 association, linking upstream kinase signaling to Polycomb function.\",\n      \"evidence\": \"Mass spectrometry site mapping, phospho-specific antibody, MEK inhibitor and EGF stimulation with Co-IP, phosphomimetic p16 repression assay\",\n      \"pmids\": [\"24194518\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Magnitude of functional effect modest\", \"Responsible kinase not directly identified\"]\n    },\n    {\n      \"year\": 2014,\n      \"claim\": \"Revealed a transcriptional-activator mode in which CBX7 cooperates with p300 to induce DKK-1 and restrain Wnt/β-catenin signaling and stem-like populations.\",\n      \"evidence\": \"ChIP for CBX7/p300 and acetylation at DKK-1, knockdown/overexpression, pharmacological DKK-1 inhibition rescue\",\n      \"pmids\": [\"25351982\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"How CBX7 switches between repressor and activator modes unknown\", \"Single lab\"]\n    },\n    {\n      \"year\": 2014,\n      \"claim\": \"Broadened the CBX7 regulon to include both repressed (SPP1) and activated (FOS/FOSB/EGR1) genes via direct promoter occupancy.\",\n      \"evidence\": \"Expression profiling after CBX7 restoration, ChIP at promoters, tissue correlation in thyroid and lung carcinoma\",\n      \"pmids\": [\"24865347\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Determinants of activation vs repression at each promoter unresolved\"]\n    },\n    {\n      \"year\": 2015,\n      \"claim\": \"Provided crystal structures of the chromodomain with inhibitors that compete with H3K27me3 and pharmacologically derepress p16, validating the methyl-lysine cage as a druggable target.\",\n      \"evidence\": \"X-ray crystallography, fluorescence polarization, ChIP displacement and expression in PC3 cells (MS37452)\",\n      \"pmids\": [\"25660273\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Inhibitor selectivity across CBX paralogs not fully resolved\"]\n    },\n    {\n      \"year\": 2016,\n      \"claim\": \"Live-cell single-molecule tracking showed CBX7 requires combinatorial H3K27me3 and DNA co-recognition via a chromodomain–ATL unit for chromatin targeting.\",\n      \"evidence\": \"Single-molecule tracking, CRISPR disruption of the H3K27me3 pathway, biochemical DNA-binding assays, CD/ATL mutants\",\n      \"pmids\": [\"27723458\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Sequence specificity of the DNA-binding unit not defined\", \"Interplay with RNA binding during targeting unresolved\"]\n    },\n    {\n      \"year\": 2016,\n      \"claim\": \"Discovered a Class B antagonist (MS351) that selectively blocks H3K27me3 binding when the chromodomain is RNA-bound, dissecting the RNA-versus-histone reading states pharmacologically.\",\n      \"evidence\": \"Crystal structure of CBX7ChD/MS351, fluorescence polarization, p16 derepression in mESC and PC3\",\n      \"pmids\": [\"27326334\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"In vivo efficacy not established\", \"Selectivity profile limited\"]\n    },\n    {\n      \"year\": 2017,\n      \"claim\": \"Transcriptome-wide CLIP defined CBX7 as an mRNA 3' UTR binder with discrete sequence motifs, expanding its RNA interactome beyond ANRIL.\",\n      \"evidence\": \"dCLIP in mouse and human cells, motif analysis, in vitro binding with motif mutants, antisense oligonucleotide intervention\",\n      \"pmids\": [\"29073373\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Functional consequence of 3' UTR binding on each transcript unclear\", \"Link between cytoplasmic RNA binding and chromatin role unresolved\"]\n    },\n    {\n      \"year\": 2017,\n      \"claim\": \"Linked CBX7 to KRAS control via positive regulation of miR-155, illustrating an indirect post-transcriptional output.\",\n      \"evidence\": \"miRNA microarray in Cbx7-null vs WT MEFs, miR-155 transfection with KRAS Western blot, colon carcinoma tissue correlation\",\n      \"pmids\": [\"28259135\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Mechanism of miR-155 promoter regulation by CBX7 not shown\", \"Single lab\"]\n    },\n    {\n      \"year\": 2018,\n      \"claim\": \"Positioned CBX7 upstream of a YAP/TAZ–CTGF–JNK axis to restrain glioma migration.\",\n      \"evidence\": \"Overexpression, GSEA, Western blot for CTGF/p-JNK, genetic rescue (CTGF OE, CA-JNK), migration assays\",\n      \"pmids\": [\"27291091\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Direct promoter targets in the axis not mapped\", \"Single lab\"]\n    },\n    {\n      \"year\": 2019,\n      \"claim\": \"Identified the H3K9 methyltransferases SETDB1, EHMT1 and EHMT2 as CBX7 partners recognized through trimethyl-lysine motifs, extending chromodomain reading to non-histone methylated proteins.\",\n      \"evidence\": \"Mass spectrometry interactome, Co-IP, SETDB1 knockdown phenocopy in AML cells, HSPC xenotransplant\",\n      \"pmids\": [\"30759399\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Direct vs bridged interactions not all resolved\", \"Single lab\"]\n    },\n    {\n      \"year\": 2019,\n      \"claim\": \"Characterized a positive allosteric modulator (UNC4976) that re-equilibrates PRC1 off H3K27me3 targets by enhancing non-specific nucleic-acid binding, refining the pharmacological model.\",\n      \"evidence\": \"Quantitative cellular chromodomain assay, ChIP displacement, fluorescence polarization, reporter assays\",\n      \"pmids\": [\"31422906\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"In vivo relevance not tested\", \"Single lab\"]\n    },\n    {\n      \"year\": 2020,\n      \"claim\": \"Showed CBX7 directly occludes the E-box to block TWIST-1-driven mesenchymal transformation in ovarian cancer.\",\n      \"evidence\": \"CRISPR/genetic CBX7 deletion, E-box reporter assays, in vivo tumorigenicity\",\n      \"pmids\": [\"32205869\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Direct CBX7–DNA contact at the E-box not structurally characterized\", \"Single lab\"]\n    },\n    {\n      \"year\": 2020,\n      \"claim\": \"Established that two CBX7 isoforms partition between nucleus and cytoplasm with opposing proliferative functions, indicating isoform-resolved biology.\",\n      \"evidence\": \"Molecular cloning, subcellular fractionation, immunofluorescence, serum starvation and proliferation assays\",\n      \"pmids\": [\"32415167\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Molecular basis of cytoplasmic p22CBX7 anti-proliferative effect unknown\", \"Single lab\"]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"Defined a CBX7/AKR1B10/ERK repressive axis in bladder cancer through PRC1-dependent transcriptional silencing.\",\n      \"evidence\": \"RNA-seq, ChIP at AKR1B10, siRNA rescue, ERK Western blot, xenografts\",\n      \"pmids\": [\"34035231\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"How AKR1B10 controls ERK not mechanistically resolved\", \"Single lab\"]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"Identified PDE4B as another directly repressed PRC1-dependent CBX7 target in bladder cancer.\",\n      \"evidence\": \"ChIP at PDE4B promoter, luciferase reporter, knockdown/overexpression\",\n      \"pmids\": [\"34977026\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Downstream signaling consequence not detailed here\", \"Single lab\"]\n    },\n    {\n      \"year\": 2022,\n      \"claim\": \"Established RNF26 as an E3 ligase driving ubiquitin-dependent CBX7 degradation, defining a route for CBX7 protein turnover in renal cancer.\",\n      \"evidence\": \"Co-IP, ubiquitination assay, cycloheximide chase, RNF26 KD/OE, xenografts\",\n      \"pmids\": [\"35342353\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Ubiquitination site on CBX7 not mapped\", \"Single lab\"]\n    },\n    {\n      \"year\": 2022,\n      \"claim\": \"Placed CBX7 in an EZH2-repressed feedback loop and showed CBX7 represses FGFR3 to sensitize bladder cancer to cisplatin via PI3K-AKT inactivation.\",\n      \"evidence\": \"ChIP-qPCR at CBX7 and FGFR3 promoters, RT-qPCR/Western blot, cisplatin sensitivity assay, xenograft\",\n      \"pmids\": [\"36396821\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Direct vs indirect PI3K-AKT modulation not separated\", \"Single lab\"]\n    },\n    {\n      \"year\": 2022,\n      \"claim\": \"Linked CBX7 to immune evasion through a CBX7/POU2F2/PD-L1 axis governing PD-1 blockade response.\",\n      \"evidence\": \"RNA-seq, Western blot/RT-qPCR for POU2F2 and PD-L1, PD-1 blockade functional assay\",\n      \"pmids\": [\"35526483\"],\n      \"confidence\": \"Low\",\n      \"gaps\": [\"POU2F2 intermediate to PD-L1 not directly demonstrated at the promoter — indirect inference\", \"Single lab\"]\n    },\n    {\n      \"year\": 2022,\n      \"claim\": \"Showed circ_0006790 promotes CBX7 nuclear translocation enabling DNMT-mediated S100A11 silencing to suppress pancreatic cancer immune escape.\",\n      \"evidence\": \"RNA pull-down/RIP, fractionation, ChIP for DNMT at S100A11, siRNA knockdowns, xenografts\",\n      \"pmids\": [\"35693076\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"How circRNA controls CBX7 trafficking mechanistically unclear\", \"Single lab\"]\n    },\n    {\n      \"year\": 2023,\n      \"claim\": \"Defined a CBX7–TARDBP–RBM38 axis driving postnatal cardiomyocyte cell-cycle exit, revealing a developmental, non-canonical CBX7 program.\",\n      \"evidence\": \"Co-IP/MS for CBX7–TARDBP, cardiac-specific KO mice, adenoviral overexpression, proliferation immunostaining, injury/regeneration models\",\n      \"pmids\": [\"37158107\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether this axis is PRC1-dependent unresolved\", \"Direct RBM38 regulation mechanism not fully mapped\"]\n    },\n    {\n      \"year\": 2024,\n      \"claim\": \"Connected CBX7 to metabolic control by showing it represses USP44, destabilizing c-MYC and reducing LDHA-driven glycolysis in meningioma.\",\n      \"evidence\": \"iTRAQ proteomics, ChIP at USP44, luciferase reporter, c-MYC stability and proteasome inhibitor assays, xenografts\",\n      \"pmids\": [\"37791390\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Direct USP44–c-MYC deubiquitination step inferred not proven here\", \"Single lab\"]\n    },\n    {\n      \"year\": 2024,\n      \"claim\": \"Showed CBX7 blocks Twist1 access to the EphA2 promoter to suppress basal-like breast cancer metastasis.\",\n      \"evidence\": \"ChIP for Twist1 at EphA2 with/without CBX7, dual-luciferase, migration/invasion assays\",\n      \"pmids\": [\"35843065\"],\n      \"confidence\": \"Low\",\n      \"gaps\": [\"Direct CBX7–Twist1 binding not characterized — competitive mechanism inferred\", \"Single lab\"]\n    },\n    {\n      \"year\": 2024,\n      \"claim\": \"Identified RNF2 as a second E3 ligase degrading CBX7 in chondrosarcoma, reinforcing ubiquitin-proteasomal control of CBX7 abundance.\",\n      \"evidence\": \"Co-IP, ubiquitination assay, cycloheximide chase, RNF2 KD/OE, xenograft\",\n      \"pmids\": [\"39456039\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Relationship between RNF2 and RNF26 in CBX7 turnover unknown\", \"Single lab\"]\n    },\n    {\n      \"year\": 2024,\n      \"claim\": \"Revealed a pro-angiogenic CBX7/HIF-1α/VEGF program under hypoxia, an activating role in vascular endothelial cells.\",\n      \"evidence\": \"Knockdown/overexpression in HCVECs, Western blot, nuclear fractionation, angiogenesis assays, laser-induced CNV mouse model\",\n      \"pmids\": [\"39179168\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Direct vs indirect HIF-1α transcriptional control unresolved\", \"Single lab\"]\n    },\n    {\n      \"year\": 2024,\n      \"claim\": \"Confirmed CBX7 partnering with EHMT1/2 and SETDB1 and showed CBX7 inhibitors disrupt these interactions, lowering H3K9 methylation and affecting H2Aub-mediated repression.\",\n      \"evidence\": \"Co-IP, pharmacological CBX7 inhibition, H3K9me and H2Aub Western blot, expression and combination growth assays\",\n      \"pmids\": [\"39613290\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Whether H3K9-MTase recruitment is direct or PRC1-bridged not resolved\", \"Single lab\"]\n    },\n    {\n      \"year\": 2025,\n      \"claim\": \"Placed CBX7 in a DNMT1/CBX7/ERK axis in pancreatic cancer, where promoter methylation silences CBX7 to relieve ERK suppression.\",\n      \"evidence\": \"ChIP for DNMT1 at CBX7 promoter, dual-luciferase, DNMT1 knockdown with CBX7/ERK readout, functional assays\",\n      \"pmids\": [\"40387566\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"How CBX7 restrains ERK mechanistically not defined\", \"Single lab\"]\n    },\n    {\n      \"year\": 2026,\n      \"claim\": \"Uncovered a lymphoid-specific, non-canonical CBX7: a cytosolic c-Raf/MEK1/2/CK2-α signaling scaffold sustaining ERK1/2 and a methylation-dependent transcriptional activator of cytokine genes.\",\n      \"evidence\": \"Co-IP, ChIP at cytokine promoters, fractionation, genetic KO and pharmacological inhibition in mouse/human lymphoid cells, RNA-seq, asthma models\",\n      \"pmids\": [\"41686891\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Molecular basis of cell-type specificity unknown\", \"How a Polycomb reader scaffolds cytosolic kinases not structurally defined\"]\n    },\n    {\n      \"year\": 2026,\n      \"claim\": \"Showed CBX7 preferentially reads Ser31-phosphorylated H3.3K27me3 and recruits KAP1 to build H3K9me3 heterochromatin, controlling retrotransposon silencing and X-inactivation.\",\n      \"evidence\": \"Nucleosome pulldown with defined modifications, H3K9me3 ChIP after disruption, retrotransposon and X-inactivation assays\",\n      \"pmids\": [\"41582043\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Structural basis of S31ph-K27me3 preference not solved\", \"Direct CBX7–KAP1 contact surface unmapped\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"How CBX7 chooses between its repressor, activator, and cytosolic-scaffold modes — and how RNA, DNA, and methyl-lysine reading are integrated to determine context-specific output — remains unresolved.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"No unifying model linking nuclear/cytoplasmic isoforms, lymphoid scaffold function, and PRC1 repression\", \"Determinants of activator vs repressor outcome at individual promoters undefined\", \"Integration of 3' UTR mRNA binding with chromatin role unknown\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0042393\", \"supporting_discovery_ids\": [1, 12, 35]},\n      {\"term_id\": \"GO:0003723\", \"supporting_discovery_ids\": [1, 14]},\n      {\"term_id\": \"GO:0003677\", \"supporting_discovery_ids\": [12, 19]},\n      {\"term_id\": \"GO:0140110\", \"supporting_discovery_ids\": [0, 7, 9, 10]},\n      {\"term_id\": \"GO:0060090\", \"supporting_discovery_ids\": [0, 5, 6, 34]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005634\", \"supporting_discovery_ids\": [0, 20]},\n      {\"term_id\": \"GO:0005829\", \"supporting_discovery_ids\": [20, 34]},\n      {\"term_id\": \"GO:0000228\", \"supporting_discovery_ids\": [35]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-4839726\", \"supporting_discovery_ids\": [0, 6, 35]},\n      {\"term_id\": \"R-HSA-74160\", \"supporting_discovery_ids\": [7, 10, 21, 22]},\n      {\"term_id\": \"R-HSA-1640170\", \"supporting_discovery_ids\": [0, 7, 27]},\n      {\"term_id\": \"R-HSA-1643685\", \"supporting_discovery_ids\": [3, 7, 24]},\n      {\"term_id\": \"R-HSA-162582\", \"supporting_discovery_ids\": [16, 21, 34]}\n    ],\n    \"complexes\": [\"PRC1\"],\n    \"partners\": [\"RING1\", \"RNF2\", \"HDAC2\", \"SUV39H2\", \"SETDB1\", \"EHMT1\", \"TARDBP\", \"KAP1\"],\n    \"other_free_text\": []\n  }\n}","audit_flag":null,"evaluation":{"pairwise":"win","faith_supported":10,"faith_total":10,"faith_pct":100.0}}